영문계약__글212건

  1. 2019.09.30 계약의 해제 또는 해지로 인한 손해배상책임의 범위 – 계약의 정상이행 시 얻을 이익, 이행이익의 범위 내에서 지출한 비용청구 인정 BUT 이행이익을 인정할 수 없는 경우라면 비용청구권 불..
  2. 2019.09.30 기술이전, 라이선스 계약 분쟁 – 대상 특허권의 무효 확정 시 장래 로열티 지급의무 부정 BUT 무효 확정 전 이미 지급한 로열티의 반환의무 부정 + 무효확정 전 미지급 로열티의 청구권 인정: ..
  3. 2019.09.27 특정제품의 판매중지명령 등 정부의 일방적 조치, 당사자의 책임 없는 사유로 발생한 사안에서 채무불이행 책임 및 손해배상책임 인정 여부 – 불가항력 (Force Majeure) 관련 법리
  4. 2019.09.27 MPQ (Minimum Purchase Quantity) 최소의무구매수량 조항의 쟁점 – 독점 수입판매계약(Exclusive Agreement)에서 최소주문수량 조건 미이행, 계약위반 시 법적 효력 - 독점권 상실 및 손해배상 책임 여부: 서..
  5. 2019.09.27 독점계약 분쟁, 독점계약(Exclusive Agreement)의 Risk 관리방안 – 최소 필수이행 조건 설정 및 비독점 전환 조항
  6. 2019.09.27 손해배상 범위쟁점 - 통상손해 vs 특별손해의 구별 기준 및 판결 사례 몇 가지
  7. 2019.09.27 손해배상 범위 쟁점 – 개발계약, 공급계약에서 약정기한까지 완성된 결과를 납품하지 못한 경우 후속 완제품 개발지연 등에 따른 특별손해 배상책임 여부
  8. 2019.09.27 납품제품의 품질불량 분쟁 - 진행성 불량 발생 시 불량원인 입증, 책임소재, 책임범위 판단 – 양품 교환, 처리비용, 완제품 관련 확대손해 등 손해배상 범위: 수원지방법원 성남지원 2018. 10. 16..
  9. 2019.09.27 주문제품의 제조납품 계약에서 품질불량 분쟁 - 발매 지연 중 시장변화 판매기회상실 상실 - 손해배상 책임의 소재: 대구고등법원 2018. 5. 11. 선고 2017나23241 판결
  10. 2019.09.27 제품개발 및 공급계약에 따라 개발완료 후 시제품 납품 BUT 발주사에서 품질 성능 불량 주장하며 분쟁상황 – 법원은 제품 미완성으로 개발회사의 개발비용 및 대금청구 – 불인정: 특허법원 2..
  11. 2019.08.28 계약체결 목표로 상당한 투자 BUT 계약체결 전 사업관계 파탄 상황 - 계약성립 불인정 상황에서 불법행위로 인한 손해배상 책임
  12. 2019.08.27 계약체결 불발 책임 쟁점 - 중소기업지원 구매조건부 신제품 기술개발과제, RFP 과제 선정된 주관기관의 과제 수행 및 성공 후 발주처 지자체와 개발제품 구매계약 체결 불발 상황 – 지자체의..
  13. 2019.06.14 국제계약, 영문계약 실무 - 기술이전, 특허실시, 신제품 개발판매 계약서에서 상표라이선스 관련 계약 조항 샘플
  14. 2019.06.13 국제계약, 영문계약 상표사용허락 라이선스 계약서 샘플 – MIT 대학 로고 상표라이선스 계약서
  15. 2019.06.13 국제계약, 영문계약 실무 - 상표사용허락 라이선스 계약서 조항 샘플
  16. 2019.06.10 기술이전, 라이선스, 특허실시, 공동연구개발 국제계약, 영문계약 실무상 기본용어 설명 참고자료 – covenant, representation, warranty 의미, 위반책임 및 차이점
  17. 2019.06.10 기술이전, 라이선스, 특허실시, 공동연구개발 국제계약서, 영문계약서에서 TAX 세무조항, RECORD, AUDIT 회계자료 감사권한 관련 계약조항 샘플
  18. 2019.06.05 독점라이선스 국제계약서에서 계약종료 시 라이센시의 보상청구 관련 주요내용, 분쟁사례, 판결 및 중재판정 요지 및 실무적 포인트 몇 가지
  19. 2019.06.05 기술이전, 라이선스, 특허실시, 공동연구개발 등 국제계약서, 영문계약서에서 미국법 FCPA, Anti-Corruption, Compliance 관련 계약조항 샘플
  20. 2019.06.05 기술이전, 라이선스, 특허실시, 공동연구개발 등 국문계약서에서 공정의무, 반부패의무, 비위행위금지, Anti-Corruption, Compliance 관련 계약조항 샘플
  21. 2019.06.05 국제계약, 영문계약에서 Anti-Corruption, Compliance 쟁점, 미국법 FCPA 관련 주요내용, 최근 제재사례 및 실무적 포인트 몇 가지
  22. 2019.06.04 국제계약, 영문계약, 특허실시, 영업비밀, 기술이전 라이선스 계약서에서 계약종료, 계약해지, TERMINATION 영문조항 샘플
  23. 2019.06.04 국제계약, 영문계약, 특허실시, 영업비밀, 기술이전 라이선스 계약서에서 기술지원 TECHNICAL ASSISTANCE 조항 샘플
  24. 2019.05.31 특허기술, 영업비밀 실시허락, 기술이전, 라이선스 영문계약서에서 진술 및 보증조항 REPRESENTATIONS AND WARRANTIES 샘플
  25. 2019.05.29 특허실시, 기술이전, 공동연구개발, 라이선스 등 국제계약에서 분쟁해결수단 중재조항 관련된 분쟁사례 및 실무적 포인트 몇 가지
  26. 2019.05.29 대한상사중재원의 조정 (Mediation) 개요 설명 – 중재(Arbitration)와 엄격하게 구별
  27. 2019.05.29 중재법 주요조항 정리
  28. 2019.05.28 특허실시, 영업비밀, 기술이전 라이선스 및 생산공급 계약서에서 LICENSE GRANT 계약조항 샘플
  29. 2019.05.23 특허실시, 기술이전, 라이선스 영문계약서에서 진술보증, 면책조항 관련 실무적 포인트 몇 가지 + 면책조항 INDEMNIFICATION, INSURANCE, LIMITATION OF LIABILITY 계약조항 샘플
  30. 2019.05.23 특허실시, 기술이전 라이선스, 공동연구개발계약에서 추가 연구개발 결과물, 개량발명 관련 계약조항 샘플, 법적 쟁점 및 실무적 대응방안 몇 가지

 

 

1. 계약의 해제 또는 해지에 따른 손해배상을 청구하는 경우 채권자가 계약이 이행되리라고 믿고 지출한 비용의 배상을 청구할 수 있는지 여부 - 인정

2. 지출비용의 배상을 인정하는 취지 / 이때 배상을 청구할 수 있는 지출비용의 범위 (이행이익의 범위 내)

3. 이행이익이 인정되지 않는 경우 지출비용의 배상의 인정 여부 부정

 

채무불이행을 이유로 계약을 해제하거나 해지하고 손해배상을 청구하는 경우에, 채권자는 채무가 이행되었더라면 얻었을 이익을 얻지 못하는 손해를 입은 것이므로 계약의 이행으로 얻을 이익, 즉 이행이익의 배상을 구하는 것이 원칙이다.

 

그러나 채권자는 그 대신에 계약이 이행되리라고 믿고 지출한 비용의 배상을 채무불이행으로 인한 손해라고 볼 수 있는 한도에서 청구할 수도 있다.

 

이러한 지출비용의 배상은 이행이익의 증명이 곤란한 경우에 그 증명을 용이하게 하기 위하여 인정되는데, 이 경우에도 채권자가 입은 손해, 즉 이행이익의 범위를 초과할 수는 없다고 보아야 한다(대법원 2002. 6. 11. 선고 20022539 판결, 대법원 2015. 5. 14. 선고 2012101695 판결, 대법원 2016. 4. 15. 선고 201559115 판결 등 참조).

 

한편, 채권자가 계약의 이행으로 얻을 수 있는 이익이 인정되지 않는 경우라면, 채권자에게 배상해야 할 손해가 발생하였다고 볼 수 없으므로, 당연히 지출비용의 배상을 청구할 수 없다.

 

첨부: 대법원 2017. 2. 15. 선고 2015235766 판결

대법원 2017. 2. 15. 선고 2015다235766 판결.pdf

KASAN_계약의 해제 또는 해지로 인한 손해배상책임의 범위 – 계약의 정상이행 시 얻을 이익, 이행이익의 범위 내

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 9. 30. 09:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

1. 사안의 개요

 

(1) 특허권자 Licensor 원고 vs licensee 피고 사이 2011 6월경 구두로원고는 피고에게 이 사건 발명에 관한 통상실시권을 허락하고, 피고는 원고에게 실시료로 월 650만 원을 지급한다.”는 이 사건 약정 체결

 

(2) 라이센시 피고가 2014. 3. 1.부터 실시료 지급을 지체하여 특허권자 원고는 2014. 5. 21. 이 사건 약정을 해지

 

(3) 그런데, 대상 특허권이 무효로 확정된 상황 해당 실시료의 지급의무 분쟁 발생    

 

2. 쟁점 및 판결요지

 

특허발명 실시계약이 체결된 이후에 계약의 대상이 된 특허가 진보성이 없다는 이유로 무효로 확정된 사안에서, 위 실시계약이 원시적 불능이라고 할 수 없으므로

(1) 특허권자가 이미 지급받은 특허실시료를 반환할 의무가 없다(대법원 201242666, 42673 판결), 또한  

(2) 특허권자는 특허무효 확정 이전에 미지급된 특허실시료의 지급을 구할 수 있다(대법원 2018287362 판결).

 

3. 대법원 판결이유

 

특허가 무효로 확정되면 특허권은 특허법 제133조 제1항 제4호의 경우를 제외하고는 처음부터 없었던 것으로 간주된다(특허법 제133조 제3). 그러나 특허발명 실시계약이 체결된 이후에 계약의 대상인 특허권이 무효로 확정된 경우 특허발명 실시계약이 계약 체결 시부터 무효로 되는지는 특허권의 효력과는 별개로 판단하여야 한다.

 

특허발명 실시계약을 체결하면 특허권자는 실시권자의 특허발명 실시에 대하여 특허권 침해로 인한 손해배상이나 그 금지 등을 청구할 수 없고, 특허가 무효로 확정되기 전에는 특허권의 독점적ㆍ배타적 효력에 따라 제3자의 특허발명 실시가 금지된다. 이러한 점에 비추어 특허발명 실시계약의 목적이 된 특허발명의 실시가 불가능한 경우가 아니라면 특허 무효의 소급효에도 불구하고 그와 같은 특허를 대상으로 하여 체결된 특허발명 실시계약이 그 계약의 체결 당시부터 원시적으로 이행불능 상태에 있었다고 볼 수는 없고, 다만 특허 무효가 확정되면 그때부터 특허발명 실시계약은 이행불능 상태에 빠지게 된다고 보아야 한다(대법원 2014. 11. 13. 선고 201242666, 42673 판결 등 참조).

 

따라서 특허발명 실시계약 체결 이후에 특허가 무효로 확정되었더라도 특허발명 실시계약이 원시적으로 이행불능 상태에 있었다거나 그 밖에 특허발명 실시계약 자체에 별도의 무효사유가 없는 한, 특허권자는 원칙적으로 특허발명 실시계약이 유효하게 존재하는 기간 동안 실시료의 지급을 청구할 수 있다. 

 

첨부: 대법원 2019. 4. 25. 선고 2018287362 판결

대법원 2019. 4. 25. 선고 2018다287362 판결.pdf

KASAN_기술이전, 라이선스 계약 분쟁 – 대상 특허권의 무효 확정 시 장래 로열티 지급의무 부정 BUT 무효 확

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 9. 30. 08:40
Trackback 0 : Comment 0

댓글을 달아 주세요


 

1. 계약당사자 일방 채무자의 고의 또는 과실 없은 경우 - 책임면제

민법 제390"채무자가 채무의 내용에 좇은 이행을 하지 아니한 때에는 채권자는 손해배상을 청구할 수 있다. 그러나 채무자의 고의나 과실 없이 이행할 수 없게 된 때에는 그러하지 아니하다."

 

당사자의 책임 없는 사유로 의무를 이행할 수 없게 되는 경우의 대표적 사례가 소위 불가항력(“Force Majeure”)을 들 수 있습니다. 불가항력(Force Majeure)의 대표적 사례는 지진, 화산폭발 등 천재지변과 전장, 내란, 테러 등 비상사태를 들 수 있습니다.

 

2. 불가항력의 인정 요건

(1) 외부성 (external) - 인간의 행위가 개입되거나 개입되지 않은 사건으로(can occur with or without human intervention), 계약 당사자가 그 원인을 제공하지 않는 것으로

(2) 예견 불가능성 (unpredictable) - 당사자들이 계약 체결 당시 합리적으로 예견할 수 없었으며(cannot have reasonably been foreseen by the parties)

(3) 회피 불가능성 (irresistible and unavoidable) - 당사자들의 통제를 벗어나 결과발생을 방지하지 못하였을(be completely beyond the parties’ control; could not have prevented its consequences) 사정

 

3. 불가항력 사유 발생의 계약법상 효과

불가항력 사유가 계속되는 동안 이행의무를 부담하는 채무자는 이행지체 책임 또는 이행불능으로 인한 손해배상 책임을 면할 수 있습니다. 불가항력의 경우 의무이행이 불능이 된 경우 뿐만 아니라 의무이행의 장애가 지속되는 동안에도 채무자의 책임이 면제되는 것입니다.

 

4. 정부의 일방적 조치로 발생한 손해에 대한 계약 당사자의 손해배상 책임 여부 불가항력 면책사유로 인정될 수 있는지 여부

 

A. 개성공단 중단조치 관련 계약상 채무불이행한 경우 채무자의 손해배상 책임 불가항력으로 인한 면책 인정한 판결

당사자에게 책임 없다는 점이 분명한 사례입니다. 계약불이행 등 손해배상책임을 물을 수 없습니다. 앞서 불가항력 요건으로 설명한 외부성, 예측 불가능성, 회피 불가능성을 모두 충족한다고 보아야 할 것이므로, 불가항력 또는 그와 유사한 면책사유로 보아야 할 것입니다.

 

서울중앙지방법원 2017. 5. 5. 선고 2016가합551507 판결에서 개성공단 중단조치로 인한 채무불이행의 경우 채무자에게 책임을 물을 수 없다고 밝혔습니다. 간략하게 판결내용을 소개하면 다음과 같습니다.

 

(1) 20161월 의류업체인 A사는 개성공단에 공장을 둔 가공업체 B사와 A사에서 원자재 공급하고, B사의 개성공단 공장에서 임가공하여 완제품 납품하는 계약 체결

(2) 한달 뒤 2월 개성공단 중단 + B사 철수 및 계약이행 불가 상황 + 개성공단 공장에 있던 A사 소유의 원자재도 가지고 나오지 못함.

(3) A사는 계약 해제하고 B사가 개성공단 밖으로 반출하는데 실패한 원자재 값 8000만원을 배상청구소송 제기

(4) 서울중앙지방법원 판결 - A사 청구기각 판결

(5) 판결이유 - "B사가 A사로부터 원자재를 돌려줄 수 없게 된 것은 북한의 개성공단 내 자산 동결 및 직원 추방 조치 때문이고, 따라서 양사간 계약은 쌍방에게 책임이 없는 사유로 이행이 불능한 상태에 이르게 된 것으로 보아야한다. 당사자 쌍방에게 책임이 없는 만큼 A사는 B사에 가공비를 지급할 채무를, B사는 A사에 가공 제품을 인도할 의무를 모두 면한다. 채무불이행에 따른 손해배상 책임도 부담하지 않는다."

 

B. 발암물질 라돈 방출 침대 매트리스 회수 조치 면책 불가

정부에서 회수 및 폐기명령을 내렸지만 제조업체의 책임을 피할 수 없는 사안입니다. 사용원료에서 라돈 발생가능성이 있다는 점과 라돈의 발암 가능성은 이미 알려진 사실입니다. 제조 또는 판매업체에서 그와 같은 사실을 구체적으로 인식하지 못했다고 하더라도 제조업체 및 판매업체의 과실 책임을 피하기 어렵습니다. 따라서 정부조치를 이유로 채무불이행 등 책임을 피할 수 없는 사안입니다. 참고로 불가항력 요건인 외부성, 예측불가능성, 회피불가능성 중 어느 것도 충족한다고 볼 수 없으므로 정부의 회수조치를 불가항력으로 볼 소지는 없습니다.

 

C. 발암 후보물질 NDMA 함유 제품의 판매중지 조치

발암 가능물질 NDMA를 함유하는 원료를 사용하여 제조한 의약품의 판매중지 또는 회수조치와 관련하여 당사자의 책임 없는 사유로 볼 수 있을지는 불명확합니다. NDMA 함유 가능성을 인지하지 못한 점, 허용함량 등 관리기준이 전혀 없다는 점, 등등 사정을 감안하면, 예견불가능성 및 회피불가능성 요건은 충족된다고 볼 여지가 있습니다.

 

그러나 NDMA2군 발암유발 물질로 분류되어 있는 점, 과학적으로 NDMA 발생가능성을 전혀 예측할 수 없다고 볼 수 없는 점 등을 고려하면 예견불가능성 및 회피불가능성 요건을 충족하지 못한다고 볼 수도 있습니다.

 

이와 같이 NDMA 함유 제품의 판매중지조치 사안은 개성공단 중단사안과는 사정이 전혀 다릅니다. 그러나 라돈방출 매트리스 회수사안과도 사정이 동일하지 않습니다. 그 양극단의 중간에 해당하는 사안이지만, 성질상 개성공단 사안보다 라돈 방출 매트리스 사안에 더 가깝다 생각합니다. 관련된 과학적, 객관적 사실에 근거한 구체적 차이점이 밝혀져야 계약당사자의 면책 가능성도 가늠해 볼 수 있을 것입니다.

 

KASAN_특정제품의 판매중지명령 등 정부의 일방적 조치, 당사자의 책임 없는 사유로 발생한 사안에서 채무불이행 책

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 9. 27. 16:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

계약조항

   

국내 총판의 최소구매수량 미이행, 계약조항 위반 상황에서 제3의 업체에서 판매권 부여

국내 독점권 보유 총판의 주장요지 국내 독점판매권 침해로 인한 손해배상 청구

 

법원 판단의 요지

 

국내 총판의 MPQ 위반으로 독점권 상실 효력 발생, 국내 총판과 협의 불필요, 사전 협의를 독점권 상실의 전제조건으로 볼 수 없음

 

 

KASAN_MPQ (Minimum Purchase Quantity) 최소의무구매수량 조항의 쟁점 – 독점 수입판매계

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 9. 27. 15:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

다양한 이유로 독점계약을 체결합니다. 그런데, 독점계약은 유리한 점도 많지만 단점도 많습니다. , 독점계약 체결 후 상황이 최초 예상과 달리 전개될 경우 당사자가 부담할 Risk가 크고 계약상 융통성이 거의 없기 때문에 그 해결도 어렵습니다. 따라서 독점계약은 체결할 때부터 관련 Risk를 두루 점검해보고 그 해결방안을 계약서에 포함시키는 것이 좋습니다.

 

예를 들어, 특허기술의 독점실시를 위한 특허권 전용실시권 설정 라이선스 계약이라면 실시자 licensee에게 최소 제조 및 판매수량 또는 최소 로열티 지급액 등을 미리 설정해 두어야 합니다. 전용실시권 설정으로 특허권자 자신도 실시할 수 없을 뿐만 아니라 제3자 실시허락도 불가능하기 때문에, 특허권자 licensor는 수익을 전혀 얻을 수 없는 상황에 처할 수도 있습니다.

 

특허기술의 독점실시 라이선스 계약뿐만 아니라 공동개발 및 독점공급계약이나 독점판매 계약에서도 유사한 Risk가 있습니다. 원료에 대한 독점공급계약을 체결하였으나 그 공급가격이 너무 비싸서 최종 제품의 경쟁력을 확보할 수 없는 경우도 있습니다. 특히 제3자로부터 훨씬 낮은 가격에 동일한 원료를 공급받을 수 있다면 그 부담은 더욱 커질 것입니다.

 

그와 같은 경우 독점계약관계를 비독점 계약관계로 전환할 수 있다면 문제를 쉽게 해결할 수 있습니다. 그런데, 독점계약이 아니라면 그 연구개발에 따른 위험을 부담하기 어렵고 일정기간 독점으로 수익성을 보장해야만 하는 경우도 많습니다. 그렇지 않다면 사업성을 확보할 수 없고, 그와 같은 사정이라면 독점계약이 아니라면 당초 성사되기 어려운 계약도 있습니다.

 

따라서, 독점계약 자체를 회피하거나 일방적으로 파기하는 것이 아니라 독점적 지위를 종결하지만 일부는 공급할 수 있도록 보장하고 일부는 제3자에게 구매하는 등의 방안으로 발생 가능한 Risk를 적절하게 관리할 수 있는 계약구조를 만드는 것이 바람직합니다.

 

독점계약에서 자주 사용되는 최소 필수 판매수량 조건이나 지급의무 최소 로열티 조건은 가장 기본적 내용입니다. 여기에 덧붙여, 독점관계를 비독점관계로 전환하는 구조도 고려할 수 있습니다.

 

예를 들면 다음과 같은 계약조항도 가능합니다. "라이센시 실시자는 특허 실시대가 중 경상로열티로 판매량의 3% 또는 연 총 *억원 중 많은 금액을 라이센서 특허권자에게 지급한다. 라이센시 실시자가 위 특허실시대가를 지급하지 못한 경우 라이센서 특허권자는 제3자에게 본 계약 대상특허의 실시를 허락할 수 있다. 이때 제3자에 대한 실시허락은 통상실시권 허여로 한다."

 

KASAN_독점계약 분쟁, 독점계약(Exclusive Agreement)의 Risk 관리방안 – 최소 필수이행 조건

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 9. 27. 14:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

통상손해란 채무불이행이나 불법행위로 발생하는 손해 중에서 사회 일반의 관념상 통상적으로 발생한다고 생각되는 범위의 손해입니다. 특별손해는 통상 손해를 넘어서 특별한 사정으로 인한 손해입니다. 이론적 구분은 쉽지만, 실제 사안에서 통상손해와 특별손해를 명확하게 구분하는 것은 쉽지 않습니다. 통상손해 뿐만 아니라 특별손해까지 있다고 생각하여 특별손해에 대한 배상을 청구하는 경우라면 법률전문가의 조력을 받는 것이 필요합니다. 아래에서 참고자료로 기본법리와 판결사례 몇 가지를 소개합니다.

 

1. 불법행위로 인한 특별손해의 명확한 사례 전신주를 충격하는 교통사고로 화학공장에 전기공급이 갑자기 중단되어 큰 손해가 발생한 경우

 

대법원 1996. 1. 26. 선고 945472 판결 요지 불법행위의 직접적 대상에 대한 손해가 아닌 간접적 손해는 특별한 사정으로 인한 손해로서 가해자가 그 사정을 알았거나 알 수 있었을 것이라고 인정되는 경우에만 배상책임이 있다.

 

가해자가 공장지대에 위치한 전신주를 충격하여 전선이 절단된 경우, 그 전선을 통하여 전기를 공급받아 공장을 가동하던 피해자가 전력공급의 중단으로 공장의 가동이 상당한 기간 중지되어 영업상의 손실을 입게 될지는 불확실하며 또 이러한 손실은 가해행위와 너무 먼 손해라고 할 것이므로, 전주 충격사고 당시 가해자가 이와 같은 소극적인 영업상 손실이 발생할 것이라는 것을 알거나 알 수 있었다고 보기 어렵지만, 이 경우 그 전신주를 통하여 전력을 공급받고 있는 인근 피해자의 공장에서 예고 없는 불시의 전력공급의 중단으로 인하여 갑자기 공장의 가동이 중단되는 바람에 당시 공장 내 가동 중이던 기계에 고장이 발생한다든지, 작업 중인 재료가 못쓰게 되는 것과 같은 등의 적극적인 손해가 발생할 수 있을 것이라는 사정은 가해자가 이를 알거나 알 수 있었을 것이라고 봄이 상당하다.”

 

2. 채무불이행으로 인한 통상손해와 특별손해의 구별 기준 판매업자의 불량상품 판매로 인해 그것을 매수한 납품업자가 거래처를 상실하여 발생한 손해

 

광주지법 2005. 6. 10. 선고 2004가합9444 판결 채무불이행으로 인한 손해배상에 있어 통상손해인지 특별손해인지 여부는 거래당사자의 직업, 거래의 형태, 목적물의 종류 및 양 등의 사정을 종합하여 당사자들이 그러한 손해의 발생을 어느 만큼 용이하게 예견할 수 있었느냐가 관건이라 할 것인바, 당사자들이 일반적·객관적으로 당연히 그 채무불이행으로부터 발생하리라고 예상하였어야 할 손해이면 통상손해의 범위 내에 포함되고, 그러한 정도까지 예상되는 것이 아니라면 특별손해로 보아야 한다.

식육판매업자는 학교급식 납품업자가 시내 여러 학교와 학교급식 납품계약을 체결하여 각 학교에 육류를 공급하고 있었고, 판매업자가 공급하는 한우고기 또한 납품업자가 학교급식용으로 납품한다는 것을 알고 있었던 점, 판매업자는 납품업자의 요청이 있을 경우 필요한 한우 부위를 납품업자에게 공급하였지만 판매업자가 공급한 한우가 어느 특정학교로 납품되는 것까지는 알 수 없었던 점, 당시 식품납품업자들의 부정납품이 사회적 문제로 대두되던 상황이었고, 특히 식육판매업을 하는 판매업자로서는 판매업자가 납품업자와 약정한 고기를 공급하지 아니하고 젖소고기를 공급하여 이러한 점이 적발되면 납품업자가 각 학교 측으로부터 불이익을 받을 수 있다는 것을 충분히 예상할 수 있었던 점 등 제반 사정에 비추어 보면,

 

판매업자가 젖소고기를 한우고기인 양 공급하는 바람에 납품업자가 젖소고기를 납품한 학교뿐만 아니라 나머지 학교로부터 학교급식 납품계약을 해지당하여 입은 손해는 일반적·객관적으로 당연히 판매업자의 채무불이행으로부터 발생하리라고 예상하였어야 할 손해의 범위에 포함된다.

 

3. 특별손해의 몇 가지 사례

 

대법원 2006. 4. 13. 선고 200575897 판결 - "매수인의 잔금지급 지체로 인하여 계약을 해제하지 아니한 매도인이 지체된 기간 동안 입은 손해 중 그 미지급 잔금에 대한 법정이율에 따른 이자 상당의 금액은 통상손해라고 할 것이지만, 그 사이에 매매대상 토지의 개별공시지가가 급등하여 매도인의 양도소득세 부담이 늘었다고 하더라도 그 손해는 사회일반의 관념상 매매계약에서의 잔금지급의 이행지체의 경우 통상 발생하는 것으로 생각되는 범위의 통상손해라고 할 수는 없고, 이는 특별한 사정에 의하여 발생한 손해에 해당한다."

 

대법원 1991. 1. 11. 선고 90다카16006 판결 - "돈을 이용하지 못함으로써 사회통념상 통상 생기는 것으로 인정되는 통상손해는 이용하지 못한 기간 동안의 이자 상당액이라 할 것이고, 그 돈을 특수한 용도에 사용하여 이자 상당액을 넘는 특별한 이득을 보았을 것인데 이를 얻지 못하게 되었다는 사정은 이른바 특별사정으로서 그로 인한 손해를 배상받자면 가해자가 그 특별사정을 알거나 알 수 있었어야 할 경우에 한하는 것이다."

 

KASAN_손해배상 범위쟁점 - 통상손해 vs 특별손해의 구별 기준 및 판결 사례 몇 가지.pdf

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 9. 27. 13:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

예를 들어, ""회사에서 신약개발을 진행하면서 ""회사에 상업적 규모의 원료합성 연구개발 및 독점 납품계약을 체결하였고, ""은 특정 일자까지 원료 몇 kg을 납품하기로 계약하였습니다. ""은 원료를 납품 받은 후 후속 임상시험 등을 진행하기 위해 적당한 병원, CRO 등 제3자와 연구개발 계약을 체결하였습니다. 그러나, ""이 그 약정기한까지 원료합성 연구개발을 완료하지 못하였고 그 결과 원료를 납품할 수 없었습니다.

 

1. 손해배상 기본 법리

"민법 제393조 제1채무불이행으로 인한 손해배상은 통상의 손해를 그 한도로 한다고 규정하고 있고, 2특별한 사정으로 인한 손해는 채무자가 이를 알았거나 알 수 있었을 때에 한하여 배상의 책임이 있다고 규정하고 있다. 1의 통상손해는 특별한 사정이 없는 한 그 종류의 채무불이행이 있으면 사회일반의 거래관념 또는 사회일반의 경험칙에 비추어 통상 발생하는 것으로 생각되는 범위의 손해를 말하고, 2의 특별한 사정으로 인한 손해는 당사자들의 개별적, 구체적 사정에 따른 손해를 말한다." (대법원 2014. 2. 27. 선고 201366904 판결 등)

 

특별손해 배상책임에 대한 요건으로서 채무자의 예견가능성은 채권성립시가 아니라 채무불이행시를 기준으로 판단하고(대법원 1985. 9. 10. 선고 84다카1532 판결), 그 예견 대상이 되는 것은 그와 같은 특별한 사정의 존재만이고 그러한 사정에 의하여 발생한 손해의 액수까지 알았거나 알 수 있어야 하는 것은 아니다. (대법원 2002. 10. 25. 선고 200223598 판결)

 

2. 법리적용 및 사안검토

원료합성 및 납품지연으로 예정된 후속 임상시험 등을 진행하지 못해 발생한 손해는 특별손해라고 할 수 있습니다. 만약 ""이 원료를 납품해야만 그 다음 단계 시험을 진행할 수 있다는 것과 ""이 원료납품을 전제로 그 다음 단계 개발을 추진한다는 사정을 잘 알고 있었다면 ""이 그 다음 단계에 구체적으로 투입하여 발생한 손해까지도 책임을 지울 수 있을 것입니다.

 

다만, 특별손해는 예외적으로 인정되는 것이므로 그 성립요건을 엄격하게 해석하고 채무자 인식에 대한 충분한 입증을 요구합니다. 특별한 사정이 없다면 통상손해에 대한 책임만 인정되고 특별손해에 대한 배상책임까지 인정받기 쉽지 않습니다.

 

실무적으로 특별손해 배상을 청구하는 소송의 대부분에서 법원은 '특별손해에 해당하는데 채무자가 그와 같은 손해가 발생하리라는 사정을 알았거나 알 수 있었다고 보기 어렵다'는 이유로 특별손해배상청구를 배척하고 있습니다. 원고청구를 배척하는 구체적 이유를 제시하는 사례는 거의 없습니다. 이론과 달리 실제 분쟁사안에서 특별손해를 배상 받는 것을 기대하기 어렵습니다.

 

3. 실무적 대응방안 계약상 손해배상예정 조항의 실효성

기한까지 ""의 계약이행이 매우 중요하고 그 기한을 넘기면 큰 손해가 예상되는 경우라면 미리 계약서에 손해배상 예정을 규정해 두는 것이 바람직합니다. 판례는 손해액 예정에 특별손해까지 포함한다는 입장입니다.

 

특별손해의 성립여부를 입증하고 다투는 것보다 그 예정된 손해액 범위까지 책임을 묻는다는 명확한 규정을 계약서에 미리 기재해 둔다면 쉽게 특별손해범위까지 배상 받을 수 있습니다. 장래 발생 가능한 상황에 대응하는 적절한 내용의 조항을 계약서를 포함하는 것이 바람직한 계약실무라 할 것입니다. 실무적으로 매우 어려운 특별손해 요건성립과 그 손해액 입증을 피할 수 있는 방안입니다.

 

KASAN_손해배상 범위 쟁점 – 개발계약, 공급계약에서 약정기한까지 완성된 결과를 납품하지 못한 경우 후속 완제품

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 9. 27. 12:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

사안의 개요

원고회사 - OEM 생산업체, 수주 납품회사 vs 피고회사 광케이블 모듈 설계, 개발회사 OEM 생산 발주회사

 

OEM 생산발주 계약서 중 품질관련 조항

 

 

제조회사 발주제품의 OEM 제조공정 품질검사 통과, 양품 출하, 납품 완료

그 후 단계 양품 중에서 “Ball lift” 불량 발생 발주회사 진행성 불량 주장

 

발주회사 주장: 사용여부와 관계 없이 시간이 경과함에 따라 불량이 발생하는 진행성 불량존재 현재 불량인지 여부와 상관 없이 전량 판매할 수 없음, 기존 판매제품도 회수, 교환 등 처리해야 함. 비용 추가 발생

 

생산회사 주장 (1) 설령 진행성 불량으로 보더라도 그 원인이 생산회사의 제조공정에 기인하는지 분명하지 않음, (2) 또한, 제품 불량 책임을 부담하더라도 그 책임범위는 불량으로 판명된 제품을 양품으로 교환해 주는 것으로 한정됨 (OEM 계약조항 적용 주장)

 

소송 중 전문가 감정 실시, 전문가 감정의견 요지 - 제조공정상 하자 의견

 

 

 

법원판단 - 제조공정상 하자 인정, 생산회사 책임 인정, 감정결과 결정적 판단 근거

 

 

생산업체의 추가 면책 주장 - 품질 통과한 양품을 납품 받은 날로부터 6개월 이후 품질 클레임 제기함, 상법상 발견할 수 없는 하자책임 기간 6개월 한정 조항 적용, 면책 주장

 

법원판단 6개월 기간 제한의 하자담보책임 아니라 계약상 의무 불완전이행으로 인한 채무불이행 책임 기간 제한 적용 안됨

 

 

KASAN_납품제품의 품질불량 분쟁 - 진행성 불량 발생 시 불량원인 입증, 책임소재, 책임범위 판단 – 양품 교환

 

[질문 또는 상담신청 입력하기]

 

   

 

작성일시 : 2019. 9. 27. 11:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

1. 사안의 개요 및 쟁점

원고 회사: 스마트폰 무선충전기 완제품 세트 제조 및 납품

피고 회사: 무선충전기 완제품 발주 및 주요 부품인 어댑터, 배터리팩, PBA(Panel Board Assembly)를 원고회사에 공급함

문제발생: PBA 불량 및 필수요건 Qi 인증 취득 못함 à 무선충전기 완제품 세트 발매지연 à 무선충전기 수요 상실 + 판매기회 상실

 

피고 발주회사 주장: 사정변경으로 계약해제, 물품대금의 3년 단기 소멸시효 완성, 원인제공자의 권리행사는 권리남용

 

2. 발주계약의 법적 성격 확정: 부대체물 제작공급 도급계약

제작의 측면에서는 도급의 성질이 있고 공급의 측면에서는 매매의 성질이 있어 대체로 매매와 도급의 성질을 함께 가지고 있으므로, 그 적용 법률은 계약에 의하여 제작 공급하여야 할 물건이 대체물인 경우에는 매매에 관한 규정이 적용되지만, 물건이 특정의 주문자의 수요를 만족시키기 위한 부대체물인 경우에는 당해 물건의 공급과 함께 그 제작이 계약의 주목적이 되어 도급의 성질을 띠게 된다(대법원 2010.11.25. 선고 201056685 판결).

 

당사자의 일방이 상대방의 주문에 따라 자기 소유의 재료를 사용하여 만든 물건을 공급하기로 하고 상대방이 대가를 지급하기로 약정하는 이른바 제작물공급계약은 부대체물 제작공급 계약으로 도급계약임

 

3. 도급계약의 해제 여부

도급인이 완성된 목적물의 하자로 인하여 계약의 목적을 달성할 수 없는 때에는 계약을 해제할 수 있으나(민법 제668), 목적물의 하자가 도급인이 제공한 재료의 성질 또는 도급인의 지시에 기인한 때에는 그러하지 아니하다(민법 제669).

 

계약의 합의해제는 당사자 쌍방의 묵시적인 합의에 의하여서도 성립되나 이를 인정하는 데는 계약의 실현을 장기간 방치한 것만으로는 부족하고 당사자 쌍방에게 계약을 실현할 의사가 없거나 계약을 포기하는 동기에서 비롯되어 장기간 방치된 것이라고 볼 수 있는 사정이 있어야만 묵시적 합의해제를 인정할 수 있다(대법원 1992. 2. 28. 선고 9128221 판결 등 참조).

 

사정변경으로 인한 계약해제계약성립 당시 당사자가 예견할 수 없었던 현저한 사정의 변경이 발생하였고 그러한 사정의 변경이 해제권을 취득하는 당사자에게 책임 없는 사유로 생긴 것으로서, 계약내용대로의 구속력을 인정한다면 신의칙에 현저히 반하는 결과가 생기는 경우에 계약준수 원칙의 예외로서 인정되는 것이고,

 

여기에서 말하는 사정이라 함은 계약의 기초가 되었던 객관적인 사정으로서, 일방당사자의 주관적 또는 개인적인 사정을 의미하는 것은 아니라 할 것이다. 또한 계약의 성립에 기초가 되지 아니한 사정이 그 후 변경되어 일방당사자가 계약 당시 의도한 계약목적을 달성할 수 없게 됨으로써 손해를 입게 되었다 하더라도 특별한 사정이 없는 한 그 계약내용의 효력을 그대로 유지하는 것이 신의칙에 반한다고 볼 수도 없다(대법원 2007. 3. 29. 선고 200431302 판결 등 참조).

 

4. 제작물공급계약, 도급계약의 대금청구권의 소멸시효

도급계약인 제작물 공급 계약에서 대금채권의 소멸시효 기산일은 제작완료일

 

참고로, 공사도급계약에서 소멸시효의 기산점이 되는 보수청구권의 지급시기는, 당사자 사이에 특약이 있으면 그에 따르고, 특약이 없으면 관습에 의하며(민법 제665조 제2, 656조 제2), 특약이나 관습이 없으면 공사를 마친 때로 보아야 한다(대법원 2017. 4. 7. 선고 201635451 등 참조)

 

5. 최종 제품의 불량에 대한 손해배상책임 여부

도급인이 제공한 재료에 의하여 완성된 목적물에 하자가 발생한 경우 도급인은 수급인에게 손해배상을 청구할 수 없음.

 

도급계약에서 완성된 목적물에 하자가 있는 경우에는 도급인은 수급인에게 하자의 보수를 청구하거나 이에 갈음하여 손해의 배상을 청구할 수 있습니다(민법 제667조 제1). 이를 수급인의 하자담보책임이라고 합니다.

 

그러나 그 하자가 도급인이 제공한 재료 또는 도급인의 지시에 의한 경우에는 수급인이 하자담보책임을 부담하지 않습니다. 다만, 수급인이 그 재료 또는 지시가 부적당함을 알고도 도급인에게 고지하지 아니하여 그러한 하자가 발생하였다면 여전히 하자담보책임을 부담합니다(민법 제669).

 

참고: 대법원 1999. 10. 12. 선고 994846판결 수급인이 완공기한 내에 공사를 완성하지 못한 채 완공기한을 넘겨 도급계약이 해제된 경우에 있어서 그 지체상금 발생의 시기는 완공기한 다음날이고, 종기는 수급인이 공사를 중단하거나 기타 해제사유가 있어 도급인이 이를 해제할 수 있을 때를 기준으로 도급인이 다른 업자에게 의뢰하여 같은 건물을 완공할 수 있었던 시점이다.”

 

도급계약에 있어 일의 완성에 관한 주장ㆍ입증책임은 일의 결과에 대한 보수의 지급을 청구하는 수급인에게 있고, 제작물공급계약에서 일이 완성되었다고 하려면 당초 예정된 최후의 공정까지 일단 종료하였다는 점만으로는 부족하고 목적물의 주요구조 부분이 약정된 대로 시공되어 사회통념상 일반적으로 요구되는 성능을 갖추고 있어야 하므로, 제작물공급에 대한 보수의 지급을 청구하는 수급인으로서는 그 목적물 제작에 관하여 계약에서 정해진 최후 공정을 일단 종료하였다는 점 뿐만 아니라 그 목적물의 주요구조 부분이 약정된 대로 시공되어 사회통념상 일반적으로 요구되는 성능을 갖추고 있다는 점까지 주장ㆍ입증하여야 합니다.

 

판례에 따르면 수급자가 계약에 기한 의무(일의 완성)를 이행하였다고 하기 위해서는 당초 예정된 최후의 공정까지 일단 종료하였다는 점에서 나아가 목적물이 약정된 대로 개발되어 사회통념상 일반적으로 요구되는 성능을 갖추고 있어야 합니다. 그리고 위 사항에 대한 입증책임은 수급자에게 있습니다. 따라서 수주자가 하자 많은 목적물을 납품하고, 목적물의 완성 여부가 다투어지는 경우 수주자가 계약에서 정한대로의 기능을 사회통념상 일반적으로 요구되는 정도로 갖추고 있음을 증명하여야 합니다.

 

실무적으로, ‘일의 완성여부는 지체상금 액수를 다투거나, 분쟁이 심화되어 수주자가 더 이상의 작업을 하지 않겠다고 선언할 경우 발주자에게 잔금지급의무가 얼마나 있는지 여부를 다투는 경우 주된 쟁점이 됩니다.

 

KASAN_주문제품의 제조납품 계약에서 품질불량 분쟁 - 발매 지연 중 시장변화 판매기회상실 상실 - 손해배상 책임

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 9. 27. 10:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

1. 사안의 개요

- 개발회사 원고 vs 발주회사 피고 - 원고가 기화식 소독기를 제작하여 피고 회사에 납품하기로 하는 제품공급계약 체결

- 원고회사에서 개발완료 및 시제품 납품

- 발주회사에서 제품 주문하지 않고 계약관계 파탄

 

계약조항

 

2. 원고 개발회사 주장요지

처음부터 개발비 지급 및 생산 발주 능력이 없는 상태에서 계약을 체결하고 원고의 디자인, 설계도면 및 영업비밀을 무단으로 제3자에게 제공하였음. 사기, 저작권법위반, 부정경쟁방지법 위반으로 고소하였는데, 검찰은 이에 대하여 불기소처분으로 종결

민사소송 제기 시제품 개발비용 지급청구 + 불법행위로 인한 손해배상 청구

 

3. 특허법원 판결요지

제작물 공급계약의 성질 판단기준 및 당사자의 권리의무 관련 법리

제작물공급계약은 대체로 매매와 도급의 성질을 함께 가지고 있으므로, 그 적용 법률은 계약에 의하여 제작 공급하여야 할 물건이 대체물인 경우에는 매매에 관한 규정이 적용되지만, 물건이 특정의 주문자의 수요를 만족시키기 위한 부대체물인 경우에는 당해 물건의 공급과 함께 그 제작이 계약의 주목적이 되어 도급의 성질을 띠게 된다.

 

제작물공급계약에서 보수의 지급시기에 관하여 당사자 사이의 특약이나 관습이 없으면 도급인은 완성된 목적물을 인도받음과 동시에 수급인에게 보수를 지급하는 것이 원칙이고, 이때 목적물의 인도는 완성된 목적물에 대한 단순한 점유의 이전만을 의미하는 것이 아니라 도급인이 목적물을 검사한 후 그 목적물이 계약내용대로 완성되었음을 명시적 또는 묵시적으로 시인하는 것까지 포함하는 의미이다.

 

한편, 도급계약에 있어 일의 완성에 관한 주장·입증책임은 수급인에게 있고, 수급인은 최후 공정을 일단 종료하였다는 점뿐만 아니라 그 목적물의 주요구조 부분이 약정된 대로 시공되어 사회통념상 일반적으로 요구되는 성능을 갖추고 있다는 점까지 주장·입증하여야 한다.

 

구체적 사안에 대한 판단

계약 내용에 따르면 기화식 소독기는 피고 회사의 수요를 만족하기 위해 제작되는 것이므로, 이 사건 계약은 특정 주문자의 수요를 만족시키기 위한 부대체물에 대한 제작물공급계약에 해당하여 도급의 성질을 띠게 되고, 원고는 개발비를 제품 납품가에 포함하여 피고 회사에 청구할 수 있도록 규정되어 있으므로, 결국 원고의 개발비용은 기화식 소독기가 피고 회사에 납품되어 그 납품대금을 지급받을 수 있을 때 지급받게 되는 것이다.

 

그런데 피고는 계속해서 원고측에 시제품 성능에 대해 문제를 제기하고 있던 상황이므로 원고가 일을 완성하여 피고들이 시제품 개발비용 지급의무를 부담한다고 볼 수 없다.

 

또한 피고의 기망행위를 전제로 한 원고의 주장은 나머지 점에 관하여 더 나아가 살필 필요 없이 이유 없고, 원고의 디자인 및 설계도면이 피고 회사에게도 전달된 사실은 인정되나, 피고들이 이를 무단으로 제3자에게 공급하고 이를 기초로 원고의 시제품과 동일 내지 유사한 제품을 생산하여 판매하였음을 인정할 증거가 없으므로, 이를 전제로 한 원고의 저작권침해 내지 영업비밀 침해 주장 역시 나머지 점에 관하여 더 나아가 살필 필요 없이 이유 없다.

 

첨부: 특허법원 2018. 10. 26. 선고 20181299 판결

 

KASAN_제품개발 및 공급계약에 따라 개발완료 후 시제품 납품 BUT 발주사에서 품질 성능 불량 주장하며 분쟁상황

특허법원 2018. 10. 26. 선고 2018나1299 판결.pdf

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 9. 27. 09:25
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

계약체결을 목표로 상당한 시간과 비용을 투자하였으나 여러 가지 이유로 계약서에 서명하기 전에 사업관계가 파탄나는 경우가 있습니다. 상당한 비용과 시간을 투입한 당사자는 상대방으로부터 아무것도 받지 못하고 그 손해를 온전히 감수한다고 억울함을 호소합니다. 무엇이든 손해를 회복할 방안은 없는지 권리구제수단을 문의하는 사례가 많습니다. 이와 같은 상황에 관한 법리와 사례를 간략하게 설명하면 다음과 같습니다. 

 

1. 계약상 책임 여부

 

계약자유의 원칙상 각 당사자는 그 의사에 따라 계약을 체결하거나 하지 않을 자유가 있습니다. 계약 과정에서 각자의 책임으로 관련 비용을 부담하는 것이 원칙입니다. 계약이 성립된 경우에만 비로소 계약상 책임이 발생합니다.

 

계약은 당사자 의사합치로 성립되는 것이므로 계약서 작성이나 서명, 날인 등은 성립요건이 아닙니다. 다만, 계약하겠다는 정도의 단순한 의사표시만으로는 계약이 성립되지 않습니다. 그 계약의 본질적 요소에 대한 당사자들 의사합치가 있어야만 합니다.

 

한편, 모든 요소에 대한 완전한 합의가 없었다고 해도 항상 계약이 불성립한 것은 아닙니다. 계약의 본질적 부분에 대한 합의가 있다면, 즉 합의되지 않은 부분이 계약의 본질적 부분에 해당하지 않을 경우라면, 합의된 부분만으로도 계약을 체결하였을 것이 인정되는 때에는 합의된 부분만으로 계약이 성립되었다고 봅니다.

 

분쟁사례로 대법원 2001. 6. 15. 선고 9940418 판결을 살펴보면, 공사도급계약에서 견적서, 이행각서, 계약보증서까지 제공하였더라도 정식 계약서를 날인하기 전에, 법원은 다음과 같은 이유로 그 계약성립을 인정하지 않았습니다.

 

"견적서는 계약 체결전 도급금액을 정하기 위한 준비행위의 성격을 가진다. 견적서를 채택하여 도급금액을 일단 정한 후 나머지 계약조건에 대하여도 합의를 하여 하도급계약을 최종적으로 완성하기로 한 것이다. 당사자들은 청약, 청약의 거절, 변경을 가한 승낙, 새로운 청약만을 교환하였을 뿐 의사의 합치는 없었다. 제출한 이행각서는 하도급계약이 성립할 경우에 이행을 하겠다는 것이고, 계약보증서도 장차 성립할 하도급계약의 이행을 담보하려는 취지에서 교부한 것에 불과하다."

 

계약이 성립되지 않았으므로 계약상 책임도 존재하지 않습니다. 일방 당사자가 이미 상당한 시간과 비용을 투입하였다고 해도 상대방에게 계약상 책임을 물을 수는 없습니다.

 

2. 불법행위 책임

 

계약협상 후 계약체결을 거절할 수 있지만 예외적으로 그 과정에서 불법행위 성립이 인정되면 불법행위로 인한 손해배상 책임을 인정할 수 있습니다.

 

대법원 2003. 4. 11. 선고 200153059 판결은 어느 일방이 교섭단계에서 계약이 확실하게 체결되리라는 정당한 기대 내지 신뢰를 부여하여 상대방이 그 신뢰에 따라 행동하였음에도 상당한 이유 없이 계약의 체결을 거부하여 손해를 입혔다면 이는 신의성실의 원칙에 비추어 볼 때 계약자유 원칙의 한계를 넘는 위법한 행위로서 불법행위를 구성한다고 판결하였습니다. 대법원 2001. 6. 15. 선고 9940418 판결도 계약상 책임은 부인하면서도 불법행위 책임을 인정하였습니다.

 

위 대법원 판결을 자세하게 분설하면, (1) 계약 협상의 한쪽 당사자("")가 상대방 당사자("")에게 교섭단계에서 계약이 확실하게 체결되리라는 정당한 기대 내지 신뢰를 부여하였고, (2) 그 상대방 당사자("")가 그와 같은 신뢰에 따라 구체적인 준비작업 등 행동을 취하였는데 불구하고, (3) 최초 신뢰를 부여한 ""이 상당한 이유 없이 계약의 체결을 거부함으로써, (4) 결국 ""에게 손해가 발생하였다면, ""은 신의성실의 원칙을 위반한 불법행위를 범하였으므로 그로 인한 손해배상책임을 진다는 것입니다.

 

어느 일방이 교섭단계에서 계약이 확실하게 체결되리라는 정당한 기대 내지 신뢰를 부여하여 상대방이 그 신뢰에 따라 행동하였음에도 상당한 이유 없이 계약의 체결을 거부하여 손해를 입혔다면 이는 신의성실의 원칙에 비추어 볼 때 계약자유 원칙의 한계를 넘는 위법한 행위로서 불법행위를 구성한다는 취지입니다. 다만, 계약자유의 원칙에 대한 예외적 책임이므로 엄격하게 제한적으로 적용합니다.

 

3. 손해배상의 범위

 

손해배상 책임이 인정된다고 하여도 그 범위는 계약이 유효하게 성립할 것으로 기대한 상대방이 투입하여 신뢰이익의 배상으로 한정됩니다. 즉 그러한 신뢰가 없었더라면 통상 지출하지 아니하였을 비용에 대하여만 배상할 책임이 있습니다. 계약 협상과정에서 통상 들어가는 비용, 즉 계약 체결여부와 무관하게 들어가는 비용까지 ""에게 책임을 물을 수 는 없습니다.

 

실제 사안에서 본다면, 손해배상범위는 계약성립을 믿고 지출된 특별한 손해에 한정되므로, 일반적으로 그 액수는 많지 않을 것입니다. 예외적으로 큰 액수의 손해발생을 주장하는 경우 그 손해배상을 청구하는 당사자가 특별한 사정의 존재를 주장 입증해야만 합니다.

 

4. 실무적 포인트  

 

계약교섭의 일방은 벤처, 오퍼상, 소규모 사업자, 소기업이고 상대방은 대기업이나 중견기업으로서 일방이 압도적 우위에 있는 경우에도 항상 계약자유의 원칙만을 강조한다면 현실과 동떨어진 공허한 소리에 가깝습니다. 계약자유의 원칙을 악용하여 상대방에서 상당한 시간과 비용을 투자한 결과를 쉽게 얻고 난 후 정식 계약을 체결하지 않는 방식으로 부당한 이익을 얻고 상대방에게 심각한 피해를 주는 사례도 많습니다. 계약서를 체결하기 전 상황에서 계약성립 인정 + 계약상 책임을 묻는 것을 기대하기 어렵습니다.

 

실무적으로 불법행위 책임을 묻는 것이 피해구제를 받는 유일한 방안입니다. 그러나 그것도 계약자유의 원칙에 대한 예외적 책임이므로 실무상 매우 엄격하고 제한적으로 허용됩니다. 현실적으로 권리구제에 성공할 가능성이 그리 높지 않다는 의미입니다.

 

그렇다고 다른 대안도 없습니다. 불법행위 성립요건을 엄밀하고 정확하게 검토하고 신중한 소송전략으로 대응해야만 원하는 피해구제를 받을 수 있을 것입니다. 참고로 상대방에게 비난할만한 사정이 있다고 해도 우리나라 손해배상 법리상 징벌적 손해배상 책임은 인정되지 않습니다. 앞서 설명한 것처럼 계약성립을 신뢰하여 지출한 비용이나 그로 인한 손해범위로 그치고 계약성립 및 이행을 가정한 이행이익을 넘지 못합니다.

 

KASAN_계약체결 목표로 상당한 투자 BUT 계약체결 전 사업관계 파탄 상황 - 계약성립 불인정 상황에서 불법행위

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 8. 28. 08:34
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

1. 구매조건부 신제품 기술개발과제 협약 체결

 

2. 기술개발과제 수행 및 경과

(1) 원고회사 주관기관 - 국책과제 기술개발과제 선정 - 정부출연금 184백만원 + 자기 부담금 투입

(2) 개발과제 수행 완료 후 성공 판정

(3) 그러나 발주처 지자체에서 신제품 구매계약 체결 거절

(4) 피고 지자체 상대로 민사소송 제기

(5) 원고 회사의 주장 요지 구매계약체결을 전제로 지자체의 채무불이행 책임 주장 + 예비적으로 구매계약 채결이 없다면 지자체의 계약체결상 과실 책임 내지 불법행위 책임 주장

 

3. 법원의 판단

1심 판결 수원지방법원 성남지원 2018. 1,. 26. 선고 2016가합1096 판결

2심 판결 서울고등법원 2018. 12. 19. 선고 20182013675 판결

판단 요지 계약성립 불인정, 채무불이행 책임 불인정 but 지자체의 불법행위 책임 인정 지자체에 대한 약 83백만원 손해배상 명령

 

4. 판결이유

(1) 계약체결 불인정

 

 

(2) 계약체결 과정상 불법행위 책임 인정

 

 

KASAN_계약체결 불발 책임 쟁점 - 중소기업지원 구매조건부 신제품 기술개발과제, RFP 과제 선정된 주관기관의

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 8. 27. 16:45
Trackback 0 : Comment 0

댓글을 달아 주세요


 

0. TRADEMARKS.

10.1 Licensed Product Marks.

(a) LICENSEE and LICENSOR agree that (i) LICENSEE shall be responsible for the selection, registration and maintenance of all Trademarks which it employs in connection with the Commercialization of any Licensed Product in the Territory under this Agreement and (ii) LICENSOR shall be responsible for the selection, registration and maintenance of all Trademarks which it employs in connection with the Commercialization of any Licensed Product outside of the Territory under this Agreement;

 

provided that each Party shall use Commercially Reasonable Efforts to differentiate Licensed Products from products marketed as of the Closing by, for example, not utilizing any Trademark in connection with the Commercialization of any Licensed Product that would be confusingly similar to any Trademark utilized in connection with the Commercialization of products marketed as of the Effective Date but, provided further that, neither Party shall be obligated to utilize, or not to utilize, any Trademark if, in such Party’s sole opinion, such utilization would (i) have a material adverse impact on Commercialization of such Licensed Product or (ii) result in material delay in achieving Regulatory Approval for Commercialization of such Licensed Product.

 

(b) Subject to Section 10.1(a), LICENSEE shall own and control all Trademarks which it employs in connection with the Commercialization of any Licensed Product in the Territory under this Agreement (“LICENSEE Licensed Product Marks”) and shall pay all costs relating thereto.

 

LICENSEE shall have the right to brand the Licensed Products in the Territory using LICENSEE Licensed Product Marks it determines appropriate for the Licensed Products, which may vary by country or within a country, and shall have the right, but no obligation, to use the LICENSOR Trademarks, subject to the license granted by LICENSOR to LICENSEE with respect to the LICENSOR TRADEMARKS pursuant to Section 10.1(c), on the labeling and packaging for Licensed Products in the Territory, and on all marketing, advertising and promotional materials associated with such Licensed Products (collectively the “LICENSEE Licensed Product Materials”);

 

provided that LICENSEE shall not, and shall ensure that its Affiliates and Sublicensees will not, make any use of (i) the Trademarks or house marks of LICENSOR (including LICENSOR’s corporate name) other than the LICENSOR Trademarks or (ii) any trademark confusingly similar to the Trademarks or house marks of LICENSOR (including LICENSOR’s corporate name), in the case of both (i) and (ii), on any LICENSEE Licensed Product Materials. Subject to the license granted by LICENSOR to LICENSEE with respect to the LICENSOR TRADEMARKS pursuant to Section 10.1(c), LICENSEE shall own all rights in the LICENSEE Licensed Product Materials.

 

(c) Subject to the terms and conditions of this Agreement, during the Term of this Agreement, LICENSOR hereby grants to LICENSEE a non-exclusive, royalty-free, sublicenseable license (i) to use LICENSOR Trademarks on all LICENSEE Licensed Product Materials in the Territory and (ii) to reproduce, prepare derivative works, distribute copies, perform, display and otherwise use LICENSOR Copyrights in connection with the exercise of the rights granted by LICENSOR to LICENSEE under the terms of this Agreement. All representations of the LICENSOR Trademarks that LICENSEE intends to use shall first be submitted to LICENSOR for approval (which shall not be unreasonably withheld or delayed) of design, color, and other details or shall be exact copies of those used by LICENSOR. All representations of the LICENSOR Trademarks that are used by LICENSEE shall comply with the reasonable usage guidelines provided by LICENSOR.

 

(d) During the Term, LICENSOR may make a written request to LICENSEE for permission to use the LICENSEE Licensed Product Marks in relation to Licensed Products in Korea. If LICENSEE consents to such use (such consent not to be unreasonably withheld), the Parties shall discuss in good faith the terms and conditions applicable to such use of the LICENSEE Licensed Product Marks, including any reasonable consideration payable with respect to such use. In the event that LICENSEE provides its consent and the Parties agree upon terms and conditions applicable to such use, all representations of the LICENSEE Licensed Product Marks that LICENSOR intends to use shall first be submitted to LICENSEE for approval (which shall not be unreasonably withheld or delayed) of design, color, and other details or shall be exact copies of those used by LICENSEE, and all representations of the LICENSEE Licensed Product Marks that are used by LICENSOR shall comply with the usage guidelines provided by LICENSEE.

 

(e) Subject to Section 10.1(a), LICENSOR shall own and control all Trademarks which it employs in connection with the Commercialization of any Licensed Product outside the Territory and in Japan under this Agreement (“LICENSOR Licensed Product Marks”) and shall pay all costs relating thereto.

 

LICENSOR shall have the right to brand the Licensed Products outside the Territory and in Japan using LICENSOR Licensed Product Marks it determines appropriate for the Licensed Products, which may vary by country or within a country, and on the labeling and packaging for Licensed Products outside the Territory and in Japan, and on all marketing, advertising and promotional materials associated with such Licensed Products (collectively the “LICENSOR Licensed Product Materials”);

 

provided that LICENSOR shall not, and shall ensure that its Affiliates and sublicensees will not, make any use of (i) the Trademarks or house marks of LICENSEE (including LICENSEE’s corporate name) or (ii) any trademark confusingly similar to the Trademarks or house marks of LICENSEE (including LICENSEE’s corporate name), in the case of both (i) and (ii), on any LICENSOR Licensed Product Materials. LICENSOR shall own all rights in the LICENSOR Licensed Product Materials.

 

10.2 No Challenge.

(a) LICENSOR recognizes the exclusive ownership by LICENSEE of all LICENSEE Licensed Product Marks. LICENSOR shall not, either while this Agreement is in effect, or at any time thereafter, register, use or challenge or assist others to challenge the LICENSEE Licensed Product Marks. LICENSOR shall not attempt to obtain any right in or to any name, logotype, trademark or trade dress confusingly similar for the marketing, sale or distribution of any goods or products, notwithstanding whether such goods or products have a different use or are dissimilar to the Licensed Products.

 

(b) LICENSEE recognizes the exclusive ownership by LICENSOR of all LICENSOR Licensed Product Marks. LICENSEE shall not, either while this Agreement is in effect, or at any time thereafter, register, use or challenge or assist others to challenge the LICENSOR Licensed Product Marks. LICENSEE shall not attempt to obtain any right in or to any name, logotype, trademark or trade dress confusingly similar for the marketing, sale or distribution of any goods or products, notwithstanding whether such goods or products have a different use or are dissimilar to the Licensed Products.

 

10.3 Proceedings.

(a) Only LICENSEE will be authorized to initiate at its own discretion legal proceedings against any infringement or threatened infringement of any LICENSEE Licensed Product Marks.

 

(b) Only LICENSOR will be authorized to initiate at its own discretion legal proceedings against any infringement or threatened infringement of any LICENSOR Licensed Product Marks.

 

10.4 Domain Names.

(a) LICENSEE shall be responsible for the registration, hosting, maintenance and defense of any domain name based on the LICENSEE Licensed Product Marks. LICENSEE may at its sole and absolute discretion register in its own name or in name of others, host on its own servers or on Third Party servers, maintain and defend such domain names and use them for websites.

 

(b) LICENSOR shall be responsible for the registration, hosting, maintenance and defense of any domain name based on the LICENSOR Licensed Product Marks. LICENSOR may at its sole and absolute discretion register in its own name or in name of others, host on its own servers or on Third Party servers, maintain and defend such domain names and use them for websites.

 

KASAN_국제계약, 영문계약 실무 - 기술이전, 특허실시, 신제품 개발판매 계약서에서 상표라이선스 관련 계약 조항

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 6. 14. 09:11
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

 

T R A D E M A R K   L I C E N S E    A G R E E M E N T

 

This License Agreement ("Agreement") is effective as of the date above the signatures of the parties below("EFFECTIVE DATE") by and between the MIT, a corporation duly organized and existing under the laws of the Commonwealth of Massachusetts, having its principal office at 77 Massachusetts Avenue, Cambridge, Massachusetts, 02139, U.S.A. ("MIT"), and ____, a corporation duly organized under the laws of __, having its principal office at ___("LICENSEE").

 

1. BACKGROUND

1.1 MIT owns rights in certain marks now and previously used by MIT and has acquired public recognition and goodwill through the use of such marks.

 

1.2 LICENSEE recognizes the goodwill appurtenant to use of said marks and desires to obtain a license to use certain of such marks. MIT is willing to grant such a license under the terms and conditions of this Agreement.

 

2. DEFINITIONS

2.1 LICENSED MARKS shall mean those marks listed in Appendix A.

2.2 LICENSED PRODUCTS shall mean the products in the categories specified in Appendix B that bear a LICENSED MARK.

2.3 TERRITORY shall mean U.S.A. and Canada only.

2.4 NET SALES PRICE shall mean LICENSEE's billing price to customers or distributors, less (1)discounts given that are customary in the trade, (2) returns, (3) transportation charges on returns if paid by LICENSEE, (4) taxes, and (5) prepaid transportation charges on LICENSED PRODUCTS SOLD by LICENSEE.

2.5 SOLD (or SALE) shall mean the first to occur of a LICENSED PRODUCT being shipped, distributed, paid for, billed or invoiced.

2.6 TERM shall mean the effective period of this Agreement, which shall commence on the EFFECTIVE DATE and which shall terminate on the fifth anniversary of the EFFECTIVE DATE.

 

3. LICENSE GRANT

3.1 Subject to the terms and conditions of this Agreement, MIT grants to LICENSEE the nonexclusive right to use, sell and have sold LICENSED PRODUCTS in the TERRITORY during the TERM hereof. In addition, MIT grants to LICENSEE, during the TERM, the nonexclusive right to manufacture and have manufactured the LICENSED PRODUCTS within and outside the United States, provided that LICENSEE and any manufacturers with whom LICENSEE subcontracts comply with MIT's Code of Conduct, further described in Paragraph 3.3.

 

3.2 LICENSEE shall not sublicense any of the rights granted hereunder.

 

3.3 LICENSEE acknowledges that MIT desires that LICENSEE not engage in practices that adversely affect the dignity and welfare of the workers who manufacture or produce the LICENSED PRODUCTS. MIT has adopted a Code of Conduct that regulates the conditions of manufacture of LICENSED PRODUCTS.  MIT has attached the current version of the Code of Conduct as Appendix C hereto, thereby becoming a part of LICENSEE's obligations under this Agreement. MIT reserves the right to amend its Code of Conduct from time to time and attach it to this Agreement. Any LICENSEE who is unable or unwilling to comply with the amended Code of Conduct, as it exists from time to time, shall be allowed to terminate this Agreement within ninety (90) days after receipt of the revised Code of Conduct from MIT.

 

4. PAYMENTS

4.1 Delivered with LICENSEE's signed Agreement, LICENSEE shall pay to MIT a non- refundable License Issue Fee of One Hundred Dollars ($100.00). This fee is not creditable to future royalties due hereunder.

 

4.2 LICENSEE shall pay to MIT an annual non-refundable, non-creditable License Maintenance Fee of One Hundred Dollars ($100.00), due on each anniversary of the EFFECTIVE DATE during the TERM.

 

4.3 In addition to the License Issue Fee and annual License Maintenance Fee, LICENSEE shall pay to MIT a continuing royalty of seven and one half percent (7.5%) of the NET SALES PRICE of all LICENSED PRODUCTS SOLD by LICENSEE. If LICENSEE has SOLD any LICENSED PRODUCTS to any party affiliated with LICENSEE, or in any way directly or indirectly related to or under common control with LICENSEE, at a price less than the regular price charged to other parties, the royalties payable hereunder shall be computed on the basis of the regular price charged to nonaffiliated parties. There shall be no deduction from the royalties owed for uncollectible accounts or for advertising or other expenses of any kind which may be incurred or paid by LICENSEE, except those specifically enumerated in Paragraph 2.4 above.

 

4.4 Royalty payments shall be due within thirty (30) days of the end of each calendar quarter and shall be accompanied by the royalty reports described in Paragraph 5.2 below. Royalty payments shall be payable in United States dollars to "Massachusetts Institute of Technology" at the location in Paragraph 12.1 below, or at such other place as MIT may reasonably designate consistent with the laws and regulations controlling in any foreign country. If any currency conversion shall be required in connection with the payment of royalties hereunder, such conversion shall be made by using the conversion rate existing in the United States, as reported in the Wall Street Journal, on the last working day of the calendar quarter of the reporting period to which such royalty payments relate.

 

4.5 The royalty payments set forth in this Agreement shall, if overdue, bear interest, to the extent permitted by law, at five (5) percentage points above the Prime Rate of interest as reported in the Wall Street Journal on the date payment is due. The payment of such interest shall not foreclose MIT from exercising any other rights it may have as a consequence of the lateness of any payment.

 

5. REPORTS AND RECORDS

5.1 LICENSEE shall keep full, true and accurate books of account containing all particulars that may be necessary for the purpose of showing the amounts payable to MIT hereunder. Such books of account shall be kept at LICENSEE's principal place of business or the principal place of business of the appropriate Division of LICENSEE to which this Agreement relates. 

 

Such books and the supporting data shall be open at all reasonable times for five (5) years following the end of the calendar year to which they pertain to the inspection of MIT or its agents for the purpose of verifying LICENSEE's royalty statement or compliance in other respects with this Agreement.

 

In the event that any audit performed under this paragraph reveals an underpayment in excess of five percent (5%), LICENSEE shall bear the full cost of such audit and shall remit any amounts due to MIT within thirty (30) days of receiving notice thereof from MIT.

 

5.2 Within thirty (30) days after each calendar quarter during the TERM, LICENSEE shall deliver to MIT true and accurate reports giving such particulars of the business conducted by LICENSEE during the preceding calendar quarter as shall be pertinent to a royalty accounting hereunder. These reports shall include at least the following: (a) A description, broken out under each individual trademark, of all LICENSED PRODUCTS manufactured and SOLD. (b) Total billings, broken out under each individual trademark, for LICENSED PRODUCTS SOLD. (c) Deductions applicable as provided in Paragraph 2.4. (d) Total royalties due. (e) Names and addresses of LICENSEE's retail sellers of LICENSED PRODUCTS.

 

5.3 With each such report submitted, LICENSEE shall pay to MIT the royalties due and payable under this Agreement. If no royalties shall be due, LICENSEE shall so report.

 

6. TERMINATION

6.1 MIT may terminate this Agreement immediately upon written notice to LICENSEE upon the following: (a) If LICENSEE shall cease to carry on its business; (b) In the event LICENSEE fails to submit timely reports or payments due hereunder, and fails to submit such reports or make such payments within thirty (30) days after receiving written notice of such failure; (c) If, after expiration of the ninety (90) day grace period set forth in Paragraph 3.3, LICENSEE fails to comply with MIT's adopted Code of Conduct or any changes thereto; or (d) In the event LICENSEE commits a material breach of its obligations under this Agreement, except for breach as described in (a) through (c) of this Paragraph, and fails to cure that breach within ninety (90) days after receiving written notice of such breach.

 

6.2 LICENSEE may terminate this Agreement for any reason, (i) upon at least six (6) months prior written notice to MIT, such notice to state the date at least six (6) months in the future upon which termination is to be effective, and (ii) upon payment of all amounts due to MIT through such termination effective date.

 

6.3 Upon termination of this Agreement for any reason, nothing herein shall be construed to release either party from any obligation that matured prior to the effective date of such termination. The following provisions shall survive the expiration or termination of this Agreement: Articles 2, 7, 10 and 13, and Paragraphs 5.1, 5.2 (obligation to provide final report and payment), 6.3, and 6.4.

 

6.4 Upon expiration or termination of this Agreement, all rights granted to LICENSEE hereunder shall cease, and LICENSEE shall refrain from further use of the LICENSED MARKS in any manner. LICENSEE acknowledges that failure to comply with this provision shall result in immediate and irreparable harm affording injunctive and any and all other appropriate relief to MIT.

 

6.5 Upon expiration or termination of this Agreement, LICENSEE shall not operate its business in any manner which would falsely suggest to the public that this Agreement is still in force or that any relationship exists between LICENSEE and M.I.T.

 

7. GOODWILL IN LICENSED MARKS

7.1 LICENSEE agrees that the essence of this Agreement is founded on the goodwill associated with the LICENSED MARKS and value of that goodwill in the minds of the consuming public. LICENSEE agrees that it is critical that such goodwill be protected and enhanced and, toward this end, LICENSEE shall not during the TERM or thereafter:

(a) attack the title or any rights of MIT in or to the LICENSED MARKS; (b) apply to register or maintain any application or registration of the LICENSED MARKS or any other mark confusingly similar thereto in any jurisdiction, domestic or foreign; (c) use any colorable imitation of any of the LICENSED MARKS, or any variant form (including variant design forms, logos, colors, or typestyles) of the LICENSED MARKS not specifically approved by MIT; (d) misuse the LICENSED MARKS; (e) take any action that would bring the LICENSED MARKS into public disrepute; (f) use the LICENSED MARKS, or any mark or name confusingly similar thereto, in its corporate or trade name; or (g) take any action that would tend to destroy or diminish the goodwill in the LICENSED MARKS.

 

7.2 All use by LICENSEE of the LICENSED MARKS shall inure to the benefit of MIT.

 

7.3 LICENSEE agrees to cooperate fully with MIT in securing and maintaining the goodwill of MIT in the LICENSED MARKS.

 

7.4 Upon becoming aware of any third party infringement of the LICENSED MARKS, LICENSEE shall promptly advise MIT of such infringement, including the name and location of such infringer.

 

8. QUALITY CONTROL; PACKAGING AND ADVERTISING APPROVAL

8.1 All LICENSED PRODUCTS shall be of a quality acceptable to MIT LICENSEE acknowledges that if LICENSED PRODUCTS manufactured and SOLD by it are of inferior quality in design, material or workmanship, the substantial goodwill that MIT possesses in the LICENSED MARKS would be impaired.

 

Accordingly, LICENSEE agrees that all LICENSED PRODUCTS shall be of high quality. To this end, LICENSEE shall furnish to MIT, free of cost, for its approval, a sample of each LICENSED PRODUCT, together with any carton or container, packing or wrapping material.  MIT shall have fourteen (14) days from receipt of each LICENSED PRODUCT in which to approve the sample.

 

In absence of approval, the sample shall be deemed as rejected as an example of the quality for the LICENSED PRODUCT. The LICENSED MARKS may be applied by LICENSEE only to such LICENSED PRODUCTS as are manufactured in accordance with the corresponding samples accepted hereunder and that have substantially the same relative quality position in the market place as do the samples thereof; provided, however, LICENSEE may furnish to MIT a further sample of any LICENSED PRODUCT of which it desires to change the quality, style and/or appearance and MIT shall have fourteen (14) days from receipt thereof in which to approve in writing said further sample. Failure to approve shall be deemed rejection thereof as an example of quality for that LICENSED PRODUCT.

 

MIT shall have the right through its employee(s) or designated representative(s) during normal business hours to inspect the facilities and product inventory of LICENSEE to assure itself that such acceptable level of quality is being maintained at all times. 8.2 Prior to any sale or commercial use, an example of each graphic design incorporating the LICENSED MARKS shall be provided to MIT for its approval and MIT shall have fourteen (14) days from receipt thereof in which to approve in writing said graphic design. Failure to approve shall be deemed as rejection thereof for that graphic design.

 

8.3 All packaging and advertising bearing the LICENSED MARKS shall be subject to the approval of MIT LICENSEE shall furnish to MIT one (1) copy of any packaging and advertisement of LICENSED PRODUCT used by LICENSEE. MIT shall have fourteen (14) days from receipt thereof in which to approve in writing the packaging or advertising materials. In the absence of approval, the packaging and advertising materials shall be deemed as rejected. LICENSEE shall furnish to MIT a further sample of packaging and advertising if it desires to change the packaging or advertising. MIT shall have fourteen (14) days to approve such changed packaging and advertising.

 

8.4 MIT's failure to approve under Paragraphs 8.1, 8.2 and 8.3 above shall be deemed rejection, unless MIT shall have requested within any such fourteen (14) day period an additional period of time (no greater than two (2) additional weeks) for further consideration of the material in question, in which case the initial period for MIT consideration and approval shall be extended by such additional period of time. MIT reserves the right to revise its quality and design criteria at any time and to rereview, pursuant to this Article 8, LICENSEE's merchandise and graphic designs for compliance with such criteria. 8.5 Graphic designs of LICENSED MARKS must conform to the MIT Merchandise Style Guide attached hereto as Appendix D, which can be changed at MIT’s reasonable discretion upon ninety (90) days notice.

 

9. MARKING

LICENSEE agrees that it shall mark the LICENSED PRODUCTS to indicate the rights of MIT in the LICENSED MARKS, including registration status of the LICENSED MARKS and that the products are manufactured pursuant to license. The LICENSED PRODUCTS or their packaging may also bear the statement "made by/for LICENSEE under license from the Massachusetts Institute of Technology, all rights reserved", and each LICENSED PRODUCT shall bear the notation " (R) " if registered for that class of goods or, if not registered for such class of goods, "TM" or other appropriate indication.  Registrations are indicated in Appendix A.

 

10. INDEMNIFICATION AND INSURANCE

10.1 LICENSEE agrees that it is wholly responsible for all products manufactured or SOLD by or for it, including all LICENSED PRODUCTS, and that MIT shall have no liability for any items, including any LICENSED PRODUCT, manufactured or SOLD by or for LICENSEE. LICENSEE shall comply with all government regulations in the manufacture, advertisement, sale, or disposal of the LICENSED PRODUCTS.

 

10.2 LICENSEE shall indemnify, defend, and hold harmless MIT and its trustees, officers, faculty, students, employees, and agents and their respective successors, heirs and assigns (the "Indemnitees"), against any liability, damage, loss, or expense (including reasonable attorneys fees and expenses) incurred by or imposed upon any of the Indemnitees in connection with any claims, suits, actions, demands or judgments arising out of any theory of liability (including without limitation actions in the form of tort, warranty, or strict liability and regardless of whether such action has any factual basis) concerning the use of any LICENSED MARK, or use, sale, manufacture, workmanship, material, design, or advertisement of any LICENSED PRODUCT, arising out of, directly or indirectly, the rights granted in this Agreement.

 

10.3 LICENSEE shall obtain and carry in full force and effect commercial general liability insurance, including product liability insurance, which shall protect LICENSEE and Indemnitees with respect to events covered by Paragraph 10.2 above. Such insurance (i) shall be issued by an insurer licensed to practice in the Commonwealth of Massachusetts or an insurer pre-approved by MIT, such approval not to be unreasonably withheld, (ii) shall list MIT as an additional insured thereunder, (iii) shall be endorsed to include product liability coverage, and (iv) shall require thirty (30) days written notice to be given to MIT prior to any cancellation or material change thereof.

 

The limits of such insurance shall not be less than One Million Dollars ($1,000,000) per occurrence with an aggregate of Two Million Dollars ($2,000,000) for bodily injury including death; and One Million Dollars ($1,000,000) per occurrence with an aggregate of Two Million Dollars ($2,000,000) for property damage. LICENSEE shall provide MIT with Certificates of Insurance evidencing compliance with this paragraph. 

 

LICENSEE shall continue to maintain such insurance after the expiration or termination of this Agreement during any period in which LICENSEE continues to make, have made, or SELL a LICENSED PRODUCT under this Agreement.

 

11. ASSIGNMENT

This Agreement is personal to LICENSEE and may not be assigned without the prior written consent of MIT, which shall not be unreasonably withheld, and the assignee or transferee must agree in writing to MIT to be bound by the terms and conditions of this Agreement prior to such assignment or transfer.

 

12. PAYMENTS, NOTICES AND OTHER COMMUNICATIONS

12.1 Any notices required or permitted under this Agreement shall be in writing, shall specifically refer to this Agreement, and shall be sent by hand, recognized national overnight courier, confirmed facsimile transmission, confirmed electronic mail, or registered or certified mail, postage prepaid, return receipt requested, to the following addresses or facsimile numbers of the parties:

 

All notices under this Agreement shall be deemed delivered when sent via confirmed electronic mail, or telecopier to the telefacsimile number identified above, or three (3) days after mailing via certified or registered mail, return receipt requested, postage prepaid, addressed to the party for whom intended, or when actually received by the party for whom intended, whichever is earlier. A party may change its contact information immediately upon written notice to the other party in the manner provided in this paragraph.

 

12.2 Any items (or packages thereof) to be shipped by LICENSEE to MIT shall be deemed sufficiently made or given on the date of receipt by MIT if such package or items are shipped prepaid via Federal Express, UPS, DHL or similar first class service to MIT at the address in Paragraph 12.1.

 

13. MISCELLANEOUS PROVISIONS

13.1 This Agreement shall be construed, governed, interpreted and applied in accordance with the internal laws of the Commonwealth of Massachusetts, U.S.A.

 

13.2 The parties hereto acknowledge that this Agreement sets forth the entire Agreement and understanding of the parties hereto as to the subject matter hereof, and shall not be subject to any change or modification except by the execution of a written instrument executed by the parties hereto.

 

13.3 The provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable under any controlling body of law, such invalidity or unenforceability shall not in any way affect the validity or enforceability of the remaining provisions hereof.

 

13.4 The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party.

 

IN WITNESS WHEREOF, the parties have caused this agreement to be executed by their duly authorized representatives.

 

KASAN_국제계약, 영문계약 상표사용허락 라이선스 계약서 샘플 – MIT 대학 로고 상표라이선스 계약서.pdf

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 6. 13. 16:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

TRADEMARK LICENSE AGREEMENT

 

THIS AGREEMENT is entered into the last date written below by and between [INSERT NAME OF LICENSOR, ENTITY TYPE, and ADDRESS] (“LICENSOR”), and [INSERT NAME OF LICENSEE, ENTITY TYPE, and ADDRESS] (“LICENSEE”).

 

WHEREAS, LICENSOR is the sole and exclusive owner of the following trademarks and registrations: [INSERT] (the “Trademarks”); and

 

WHEREAS, LICENSOR has the power and authority to grant to LICENSEE the right, privilege and license to use the Trademarks on or in association with the goods and/or services covered by the registrations (the “Licensed Products”); and

 

WHEREAS, LICENSEE has represented that it has the ability to manufacture, market and distribute the Licensed Products in [INSERT TERRITORY] (the "Territory") and to use the Trademarks on or in association with the Licensed Products; and

 

WHEREAS, LICENSEE desires to obtain from LICENSOR a license to use, manufacture, have manufactured and sell Licensed Products in the Territory and to use the Trademarks on or in association with the Licensed Products; and

 

WHEREAS, both LICENSEE and LICENSOR are in agreement with respect to the terms and conditions upon which LICENSEE shall use the Trademarks;

 

NOW, THEREFORE, in consideration of the promises and agreements set forth herein, the parties, each intending to be legally bound hereby, do promise and agree as follows.

 

1.  LICENSE GRANT

A.  LICENSOR hereby grants to LICENSEE a non-exclusive license to use the Trademarks on or in association with the Licensed Products in the [INSERT TERRITORY] (Territory), as well as on packaging, promotional and advertising material associated therewith. 

 

B.  LICENSOR hereby grants to LICENSEE the non-exclusive right and license to use, manufacture, have manufactured, sell, distribute, and advertise the Licensed Products in the Territory.  It is understood and agreed that this license shall pertain only to the Trademarks and the Licensed Products and does not extend to any other mark, product or service.

 

C.  LICENSEE may not grant any sublicenses to any third party without the prior express written consent of the LICENSOR which may be withheld for any reason.

 

2.  TERM OF THE AGREEMENT

This Agreement and the provisions hereof, except as otherwise provided, shall be in full force and effect commencing on the last the date of execution below and shall extend for [INSERT LENGTH OF TERM] (the “Term”).

 

3.  COMPENSATION

A.  In consideration for the licenses granted hereunder, LICENSEE agrees to pay to LICENSOR a royalty of ____% (the “Royalty”) based on LICENSEE’s Net Sales of Licensed Products, accruing upon the sale of the Licensed Products (i.e., when the Licensed Product is billed, invoiced, shipped, or paid for, whichever is first regardless of the time of collection by LICENSEE), calculated on a quarterly calendar basis (the "Royalty Period") and shall be payable no later than thirty (30) days after the termination of the preceding full calendar quarter, i.e., commencing on the first (1st) day of January, April, July, and October, with late payments incurring interest at the rate of ONE PERCENT (1%) per month from the date such payments were originally due.

 

B.  In the event that LICENSEE grants any previously approved sub-licenses for the use of the Trademarks in countries outside of the United States, LICENSEE shall pay LICENSOR FIFTY PERCENT (50%) of the gross income received by LICENSEE from such sub-licensees.

 

C.  LICENSEE shall provide LICENSOR with a written royalty statement in a form acceptable to LICENSOR each Royalty Period whether or not any Licensed Products were sold during that Period and the receipt or acceptance by LICENSOR of any royalty statement or payment shall not prevent LICENSOR from subsequently challenging the validity or accuracy of such statement or payment.

 

D.  "Net Sales" shall mean LICENSEE's gross sales (the gross invoice amount billed customers) of Licensed Products, less discounts and allowances actually shown on the invoice and less any bona fide returns.  No other costs incurred in the manufacturing, selling, advertising, and distribution of the Licensed Products or any uncollectible accounts or allowances shall be deducted.   

          

4.  AUDIT

A.  LICENSOR shall have the right, upon at least five (5) days written notice to inspect LICENSEE's books and records and all other documents and material in the possession of or under the control of LICENSEE with respect to the subject matter of this Agreement at a location in the United States.  LICENSOR shall have free and full access thereto for such purposes and shall be permitted to make copies thereof and extracts therefrom.

 

B.  In the event that such inspection reveals a discrepancy in the amount of Royalty owed LICENSOR from what was actually paid, LICENSEE shall pay such discrepancy, plus interest, calculated at the rate of ONE AND ONE-HALF PERCENT (1 1/2%) per month.  In the event that such discrepancy is in excess of ONE THOUSAND UNITED STATES DOLLARS ($1,000.00), LICENSEE shall also reimburse LICENSOR for the cost of such inspection including any attorney's fees incurred in connection therewith.

 

C.  All books and records relative to LICENSEE's obligations hereunder shall be maintained and kept accessible and available to LICENSOR for inspection in the United States for at least three (3) years after termination of this Agreement.

 

D.  In the event that an investigation of LICENSEE's books and records is made, certain confidential and proprietary business information of LICENSEE may necessarily be made available to the person or persons conducting such investigation.  It is agreed that such confidential and proprietary business information shall be retained in confidence by LICENSOR and shall not be used by LICENSOR or disclosed to any third party for a period of two (2) years from the date of disclosure, or without the prior express written permission of LICENSEE unless required by law.  It is understood and agreed, however, that such information may be used in any proceeding based on LICENSEE's failure to pay its actual Royalty obligation.

 

5.  WARRANTIES AND OBLIGATIONS

A.  LICENSOR represents and warrants that it has the right and power to grant the licenses granted herein and that there are no other agreements with any other party in conflict herewith.

 

B.  LICENSOR further represents and warrants that to the best of its knowledge, the Trademarks do not infringe any valid right of any third party.

 

C.  LICENSEE represents and warrants that it will use its best efforts to promote, market, sell, and distribute the Licensed Products.

 

D.  LICENSEE shall be solely responsible for the manufacture, production, sale, and distribution of the Licensed Products and will bear all related costs associated therewith.

 

E.  It is the intention of the parties that LICENSEE shall introduce the Licensed Products in all countries in the Territory on or before [INSERT DATE].  Failure to meet this deadline shall constitute grounds for immediate termination of this Agreement by LICENSOR.

 

6.  NOTICES, QUALITY CONTROL AND SAMPLES

A.  The licenses granted hereunder are conditioned upon LICENSEE's full and complete compliance with the marking provisions of the patent, trademark and copyright laws of the United States and other countries in the Territory.

 

B.  The Licensed Products, as well as all promotional, packaging, and advertising material relative thereto, shall include all appropriate legal notices as required by LICENSOR.  [INSERT REQUIRED NOTICE].

          

C.  The Licensed Products shall be of a high quality which is at least equal to comparable products previously manufactured and marketed by LICENSEE under the trademarks and in conformity with a standard sample approved by LICENSOR.

          

D.  If the quality of a class of the Licensed Products falls below such a production-run quality, as previously approved by LICENSOR, LICENSEE shall use its best efforts to restore such quality.  In the event that LICENSEE has not taken appropriate steps to restore such quality within thirty (30) days after notification by LICENSOR, LICENSOR shall have the right to terminate this Agreement and require that the LICENSEE cease using the Trademarks.

 

E. Prior to the commencement of manufacture and sale of the Licensed Products, LICENSEE shall submit to LICENSOR, at no cost to LICENSOR and for approval as to quality, six (6) sets of samples of all Licensed Products which LICENSEE intends to manufacture and sell and one (1) complete set of all promotional and advertising material associated therewith. Failure of LICENSOR to approve such samples within thirty (30) working days after receipt thereof will be deemed approval.  Once such samples have been approved by LICENSOR, LICENSEE shall not materially depart therefrom without LICENSOR's prior express written consent, which shall not be unreasonably withheld. 

 

F.  At least once during each calendar year, LICENSEE shall submit to LICENSOR, for approval, an additional six (6) sets of samples. 

 

G.  The LICENSEE agrees to permit LICENSOR or its representative to inspect the facilities where the Licensed Products are being manufactured and packaged. 

 

7.  NOTICE AND PAYMENT

A.  Any notice required to be given pursuant to this Agreement shall be in writing and delivered personally to the other designated party at the above stated address or mailed by certified or registered mail, return receipt requested or delivered by a recognized national overnight courier service, except e-mail may be used for day-to-day operations and contacts but not for ‘notice’ or other communications required under this agreement or by law.

 

B.  Either party may change the address to which notice or payment is to be sent by written notice to the other in accordance with the provisions of this paragraph.

 

8.  PATENTS, TRADEMARKS AND COPYRIGHTS

A.  LICENSOR shall seek, obtain and, during the Term of this Agreement, maintain in its own name and at its own expense, appropriate protection for the Trademarks, and LICENSOR shall retain all right, title and interest in the Trademarks as well as any modifications made to the Trademarks by LICENSEE.  LICENSEE agrees that its use of the Trademarks inures to the benefit of LICENSOR and that the LICENSEE shall not acquire any rights in the Trademarks.

 

B.  The parties agree to execute any documents reasonably requested by the other party to effect any of the above provisions.

 

C.  LICENSEE acknowledges LICENSOR's exclusive rights in the Trademarks and, further, acknowledges that the Trademarks are unique and original to LICENSOR and that LICENSOR is the owner thereof.  LICENSEE shall not, at any time during or after the effective Term of the Agreement dispute or contest, directly or indirectly, LICENSOR's exclusive right and title to the Trademarks or the validity thereof.  LICENSOR, however, makes no representation or warranty with respect to the validity of any patent, trademark or copyright which may issue or be granted therefrom.

 

9.  TERMINATION OR EXPIRATION

A.        In addition to the termination rights that may be provided elsewhere in this Agreement, either party may terminate this Agreement upon thirty (30) days written notice to the other party in the event of a breach of a material provision of this Agreement by the other party, provided that, during the thirty (30) day period, the breaching party fails to cure such breach.  Upon expiration or termination, all Royalty obligations, including any unpaid portions of the Guaranteed Minimum Royalty, shall be accelerated and shall immediately become due and payable, and LICENSEE's obligations for the payment of a Royalty and the Guaranteed Minimum Royalty shall survive expiration or termination of this Agreement and will continue for so long as LICENSEE continues to manufacture, sell or otherwise market the Licensed Products.

 

B.        Upon expiration or termination, LICENSEE shall provide LICENSOR with a complete schedule of all inventory of Licensed Products then on-hand (the "Inventory").

 

C.  Upon expiration or termination, except for reason of a breach of LICENSEE's duty to comply with the quality control or legal notice marking requirements, LICENSEE shall be entitled, for an additional period of three (3) months and on a nonexclusive basis, to continue to sell such Inventory.  Such sales shall be made subject to all of the provisions of this Agreement and to an accounting for and the payment of a Royalty thereon, due and paid within thirty (30) days after the close of the three (3) month period.

 

D.  Upon the expiration or termination of this Agreement, all of the rights of LICENSEE under this Agreement shall terminate and immediately revert to LICENSOR and LICENSEE shall immediately discontinue all use of the Trademarks at no cost whatsoever to LICENSOR, and LICENSEE shall immediately return to LICENSOR all material relating to the Trademarks including at no cost to LICENSOR.

          

10.  GOOD WILL

LICENSEE recognizes the value of the good will associated with the Trademarks and acknowledges that the Trademarks and all rights therein including the good will pertaining thereto, belong exclusively to LICENSOR. 

 

11.  INFRINGEMENTS

If an action for infringement of the rights licensed in this Agreement is brought, each party shall execute all papers, testify on all matters, and otherwise cooperate in every way necessary and desirable for the prosecution of any such lawsuit.

 

12.  INDEMNITY

LICENSEE agrees to defend and indemnify LICENSOR, its officers, directors, agents and employees, against all costs, expenses and losses (including reasonable attorneys' fees and costs) incurred through claims of third parties against LICENSOR based on the manufacture or sale of the Licensed Products including, but not limited to, actions founded on product liability. 

 

13.  INSURANCE

LICENSEE shall, throughout the Term of the Agreement, obtain and maintain at its own cost and expense from a qualified insurance company licensed to do business in California, standard Product Liability Insurance naming LICENSOR as an additional named insured.  Such policy shall provide protection against any and all claims, demands and causes of action arising out of any defects or failure to perform, alleged or otherwise, of the Licensed Products or any material used in connection therewith or any use thereof.  The amount of coverage shall be a $10 million combined single limit for each single occurrence for bodily image and/or property damage.  The policy shall provide for ten (10) days notice to LICENSOR from the insurer by Registered or Certified Mail, return receipt requested, in the event of any modification, cancellation or termination thereof.  LICENSEE agrees to furnish LICENSOR a certificate of insurance evidencing same within thirty (30) days after execution of this Agreement and, in no event shall LICENSEE manufacture, distribute or sell the Licensed Products prior to receipt by LICENSOR of such evidence of insurance.

 

14.  JURISDICTION AND DISPUTES

A.  This Agreement shall be governed in accordance with the laws of the State of California, United States of America.

 

B.  Any controversy, claim or dispute arising out of or relating to this Agreement or the breach, termination, enforcement, interpretation or validity thereof, including the determination of the scope or applicability of this agreement to arbitrate (except at the option of either party for any application for injunctive relief) shall be finally settled by arbitration in Los Angeles County, California under the rules of the American Arbitration Association (AAA) before one arbitrator and judgment upon the award rendered may be entered in any court having jurisdiction.  In this regard, the parties submit to the personal subject matter jurisdiction of the State of California.  The arbitration provisions of this Section shall be interpreted according to, and governed by, the Federal Arbitration Act, and any action to enforce any rights hereunder shall be brought exclusively in the U.S. District Court for the Central District of California.  EACH PARTY HERETO KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVES ANY RIGHT TO A TRIAL BY JURY OF ANY DISPUTE RELATING TO THIS AGREEMENT AND AGREES THAT ANY SUCH ACTION SHALL BE ADJUDICATED BY AN ARBITRATOR AND WITHOUT A JURY.

 

C.  The parties may mutually agree upon any procedure for appointing the arbitrator and shall inform the AAA administrator as to such procedure; however, if within 45 days after the commencement of the arbitration, all of the parties have not mutually agreed on a procedure for appointing the arbitrator or have not mutually agreed on the designation of the arbitrator, the AAA administrator shall unilaterally appoint and designate the presiding arbitrator.

 

D.  If a party fails to file a statement of defense within the time established by the tribunal without showing sufficient cause for such failure, as determined by the tribunal, or if a party, duly notified, fails to appear at a hearing without showing sufficient cause for such failure, as determined by the tribunal, the tribunal may proceed with the arbitration; or if a party, duly invited to produce evidence or take any other steps in the proceedings fails to do so within the time established by the tribunal without showing sufficient cause for such failure, as determined by the tribunal, the tribunal may make the award on the evidence before it.

 

E.  The arbitrator may, in the Award, allocate all or part of the costs of the arbitration, including the fees of the arbitrator and the reasonable attorneys’ fees of the prevailing party.

 

15.  AGREEMENT BINDING ON SUCCESSORS

The provisions of this Agreement shall be binding on and shall inure to the benefit of the parties hereto, and their heirs, administrators, successors, and assigns.

 

16.  WAIVER

No waiver by either party of any default shall be deemed as a waiver of prior or subsequent default of the same or other provisions of this Agreement.

 

17.  SEVERABILITY

If any term, clause, or provision hereof is held invalid or unenforceable by a court of competent jurisdiction, such invalidity shall not affect the validity or operation of any other term, clause or provision and such invalid term, clause or provision shall be deemed to be severed from the Agreement.

 

18.  NO JOINT VENTURE

Nothing contained herein shall constitute this arrangement to be employment, a joint venture or a partnership.

 

19.  ASSIGNABILITY

The license granted hereunder is personal to LICENSEE and shall not be assigned by any act of LICENSEE or by operation of law unless in connection with a transfer of substantially all of the assets of LICENSEE or with the consent of LICENSOR.

 

20.  GOVERNMENTAL APPROVAL

As promptly as possible after execution of this Agreement, LICENSEE agrees to submit copies of this Agreement to any governmental agency in any country in the Territory where approval of a license agreement is necessary and agrees to promptly prosecute any such application diligently.  This Agreement shall only become effective in such country or countries upon receipt of appropriate approval from the applicable governmental agency.

 

21.  INTEGRATION

This Agreement constitutes the entire understanding of the parties, and revokes and supersedes all prior agreements between the parties, including any option agreements which may have been entered into between the parties, and is intended as a final expression of their Agreement.  It shall not be modified or amended except in writing signed by the parties hereto and specifically referring to this Agreement.  This Agreement shall take precedence over any other documents which may be in conflict with said Agreement.

 

22.  AMENDMENTS

Any amendment to this Agreement must be in writing and signed by an authorized person of each party.

 

 

 

 

IN WITNESS WHEREOF, the parties hereto, intending to be legally bound hereby, have each caused to be affixed hereto its or his/her hand and seal the day indicated.

 

[INSERT NAME OF LICENSOR]  [INSERT NAME OF LICENSEE]

 

By:                                                         By: 

Title:                                              Title: 

Date:                                            Date: 

 

KASAN_국제계약, 영문계약 실무 - 상표사용허락 라이선스 계약서 조항 샘플.pdf

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 6. 13. 08:27
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

A covenant is a promise by a party by which it pledges that something is either done, will be done or shall not be done.

      Example 1: “Licensee shall pay Licensor a flat royalty based on 2.5% of Gross Revenues received from the sale of Licensed Products.”

      Example 2: “Company A hereby covenants not to sue Company B under any patent listed in Exhibit A for infringement based upon any act by Company B of manufacture, use, sale, offer for sale or import that occurs after the Effective Date.”

 

A representation is a statement of fact that induces a party to enter into the contract. The statement, made before or at the time of making the contract, regards a past fact or existing circumstance related to the contract which influences such party to enter the contract.

      Example 1: “Licensor represents to Licensee that it has the full and unencumbered right, power and authority to enter into this Agreement and to grant the license rights granted by Licensor to Licensee hereunder.

      Example 2: “Company A hereby represents that it owns full legal and equitable title to each patent listed in Exhibit A.”

 

A warranty is an undertaking or stipulation that a certain fact in relation to the subject of the contract is or shall be as it is stated or promised; and refers to an agreement to protect the recipient against loss if the fact is or becomes untrue (i.e., an implied indemnification).

      Example 1: “Licensor warrants to Licensee that it has not received any written notice or claim, and is not otherwise aware that the Licensed Technology infringes or misappropriates the proprietary rights of any other Person.”

      Example 2: “Company A warrants to Company B that the Technical Information provided hereunder will be the same as that used in the design, production, installation, and maintenance of Licensed Products produced in its own factories.”

 

A claim for breach of a covenant may be for damages or specific performance. When a breach of a covenant is “material” (i.e., a breach that destroys the value of the contract for the non-breaching party), however, it excuses the non-breaching party’s performance.  This often is subjective and can be expensive to prove in later litigation. (Thus, the more specificity drafted into a contract – i.e., a listing of the specific and most-likely events that trigger a termination event – the better that contract protects the parties.)

 

Upon a false representation (or misrepresentation), however, the defrauded party may elect to void the entire contract and recover any sums paid.

 

When a breach of warranty occurs, the damages recoverable are the difference in the value as warranted (i.e., how they should have been) and the value as received.

 

This is because “representations” should be statements made by a party after investigation and with a belief that such statements are true, and “warranties” should be statements a party makes while willing to accept financial responsibility if the statement turns out to be untrue, regardless of whether they actually (or should have) investigated.

 

In sum, upon a breach of a covenant or breach of warranty, the contract remains binding and damages only are recoverable for the breach; whereas, upon a misrepresentation, the defrauded party may elect to void the entire contract. 

 

KASAN_기술이전, 라이선스, 특허실시, 공동연구개발 국제계약, 영문계약 실무상 기본용어 설명 참고자료 – cov

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 6. 10. 11:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

Taxes; Withholding.

Each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the efforts of the Parties under this Agreement. 

 

In the event that any payment under this Agreement becomes subject to withholding taxes, other than income tax, under Applicable Laws, the payor may withhold from the payment the amount of such taxes due. 

 

Payor will timely pay to the proper governmental authority the amount of any taxes withheld and will provide the payee with an official tax certificate or other evidence of tax obligation together with proof of payment from the relevant governmental authority sufficient to enable payee to claim such payment of taxes. 

 

The Parties agree to cooperate with one another and use reasonable efforts to minimize or eliminate such tax withholding or similar obligations in respect of royalties, milestone payments, and any other payments made by Licensee to Licensor under this Agreement.  The Parties shall, wherever possible, endeavour and cooperate to minimize the taxes due under this Agreement.   

 

Records; Audits. 

Licensee and its Affiliates will maintain, and Licensee will cause each of its Sublicensees, if any, to maintain, complete and accurate records in sufficient detail to confirm the accuracy of the calculation of royalty payments and the achievement of milestone events, for a period of three (3) years after the Calendar Year in which such sales or events occurred or for the period required under the Applicable Laws, whichever is longer. 

 

Upon reasonable prior notice and without disruption to Licensee’s business, such records of Licensee and its Affiliates and Sublicensees shall be made available during regular business hours for a period of three (3) years from the end of the Calendar Year to which they pertain for examination, and not more often than once each Calendar Year, by an independent certified public accountant among the major internationally reputable accounting firms selected by Licensor, for the sole purpose of and only to the extent necessary for verifying the accuracy of the financial reports furnished by Licensee pursuant to this Article 8. 

 

Such independent accountant shall disclose to Licensor only the amounts that such independent accountant believes to be due and payable hereunder to Licensor, details concerning any discrepancy from the amount paid and the amount due, and shall disclose no other information revealed in such audit. 

 

Any and all records examined by such independent accountant shall be deemed Licensee’s Confidential Information which may not be disclosed by such independent accountant to any Third Party, and Licensee may require such independent accountant to enter into an appropriate written agreement obligating it to be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are no less protective than those set forth in Article 16. 

 

If, as a result of any inspection of the books and records of Licensee, it is shown that payments under this Agreement were less than the amount which should have been paid, then Licensee shall make all payments required to be made plus interest (as set forth in Section 8.7) from the original due date to eliminate any discrepancy revealed by such inspection within thirty (30) days. 

 

If, as a result of any inspection of the books and records of Licensee, it is shown that payments under this Agreement were more than the amount which should have been paid, then Licensor shall, at Licensee’s election, either make all payments required to be made to eliminate any discrepancy revealed by such inspection within ninety (90) days or credit such amounts to Licensee against future payments. 

 

Licensor shall pay for such audits, except that in the event that the audited amounts were underpaid by Licensee by more than five percent (5%) of the undisputed amounts that should have been paid during the period in question as per the audit, Licensee all pay the costs of the audit.

 

KASAN_기술이전, 라이선스, 특허실시, 공동연구개발 국제계약서, 영문계약서에서 TAX 세무조항, RECORD,

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 6. 10. 09:16
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

 

KASAN_독점라이선스 국제계약서에서 계약종료 시 라이센시의 보상청구 관련 주요내용, 분쟁사례, 판결 및 중재판정

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 6. 5. 17:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

4.1. Compliance with Legal Requirements.

Licensee shall conduct, and shall ensure that its Affiliates, Sublicensees and Subcontractors, conduct, all activities hereunder, including all Development and Commercialization of the Product, in compliance with all Applicable Laws.

 

In addition, Licensee hereby certifies that (i) to its reasonably knowledge or belief, neither Licensee nor its Affiliates has been, prior to the Effective Date debarred under United States law, including Section 21 U.S.C. 335a (or any foreign equivalent thereof), and (ii) neither Licensee nor its Affiliates will, from and after the Effective Date, employ or otherwise use in any capacity, the services of any Person, who to the knowledge or belief of Licensee or any of its Affiliates is, debarred under United States law, including Section 21 U.S.C. 335a (or any foreign equivalent thereof) to perform any portion of the activities hereunder, including any Development and Commercialization of the Product.

 

Licensee shall notify Sub-Licensor in writing promptly upon becoming aware of any such debarment of any such Person, and shall, upon becoming so aware, promptly remove such Person from performing any such activities and from any function or capacity related to any such activities.

 

4.2. Compliance with Ethical Business Practices.

(a) Compliance with Laws and Policies.

Licensee shall conduct the activities contemplated herein, and shall ensure that its Affiliates, Sublicensees and Subcontractors, conduct the activities contemplated herein, in a manner which is consistent with all Applicable Laws in Korea including, as applicable, Good Clinical Practices, Good Laboratory Practices, the U.S. Foreign Corrupt Practices Act which generally prohibits the promise, payment or giving of anything of value either directly or indirectly to any Official for the purpose of obtaining or retaining business or any improper advantage, and the UK Bribery Act of 2010 which additionally includes the prohibition on the making of any bribe to a foreign public official with the intention of influencing such person in order to obtain or retain business or an advantage in the conduct of business, and good business ethics.

 

(b) Governments and International Public Organizations.

Licensee warrants that, in connection with this Agreement and Licensee’s business relating thereto, Licensee, its directors, employees, officers, and anyone acting on Licensee’s behalf or with Licensee’s knowledge, shall not offer, make or promise any payment, and shall ensure that its Affiliates, Sublicensees and Subcontractors, do not offer, make or promise any payment (either directly or indirectly, of money or other assets) to any government officials (including any government-owned or controlled commercial enterprise), or political party officials, officials of international public organizations, candidates for public office, or representatives of other businesses or persons acting on behalf of any of the foregoing (hereinafter collectively referred as “Officials”) where such payment (either directly or indirectly of money or other assets) would constitute a violation of any Applicable Law.

 

In addition, Licensee shall make no payment (either directly or indirectly of money or other assets), and shall ensure that its Affiliates, Sublicensees and Subcontractors, make no payment in connection with this Agreement or Licensee’s business relating thereto, either directly or indirectly to Officials if such payment (either directly or indirectly of money or other assets) is for the purpose of (i) influencing decisions or actions with respect to the subject matter of this Agreement or any other aspect of either Party’s business; (ii) inducing such Official to do or omit to do any action in violation of the lawful duty of such Official; (iii) securing any improper advantage; or (iv) inducing such Official to use his/her position to affect or influence any decisions or actions of government or any legislative, administrative, public agency or other public body with respect to any activities undertaken relating to this Agreement.

 

Additionally, Licensee will make reasonable efforts to comply with requests for information, including answering questionnaires and narrowly tailored audit inquiries, to the extent they relate to the subject of this Agreement, to enable Licensor to ensure compliance with any applicable anti-corruption laws.

 

(c) Disclosure.

Where Licensor requests reasonable information regarding disclosure of any officers, employees, owners, or persons directly or indirectly retained by Licensee who are Officials or relatives of Officials of any governmental authority with oversight over the performance of Licensee’s obligations under this Agreement or any Regulatory Documentation, if such persons are engaged to perform Licensee’s obligations under this Agreement, Licensee shall provide complete and accurate information and documentation to Licensor with respect thereto. Licensee shall update such disclosures upon request of Licensor from time to time as necessary to ensure the information provided remains complete and accurate for the Term of this Agreement.

 

(d) Books and Records.

Licensee represents, warrants and covenants that all books, records, invoices and other documents relating to payments and expenses under this Agreement are and shall be complete and accurate and reflect in reasonable detail the character and amount of transactions and expenditures. Licensee further represents, warrants and agrees that no “off the books” or similar funds will be maintained or used in connection with this Agreement.

 

(e) Compliance Training.

Licensee agrees to ensure that all of Licensee’s employees involved in performing the obligations under this Agreement are made specifically aware of the compliance requirements under Sections 4.2(a), (b), (d), (e) and (f).

 

(f) Exclusions Lists.

Licensee shall not use (and shall cause its Affiliates not to use) any Person (including any employee, officer, director, Sublicensee or Third Party contractor) who is (or has been) on the Exclusions List, or who is (or has been) in Violation, in the performance of any activities hereunder. Licensee certifies to Sub-Licensor that as of the Effective Date, Licensee has screened itself, and its officers and directors (and its Affiliates, Sublicensees and Third Party contractors and their respective officers and directors) against the Exclusions Lists and that it has informed Licensor whether Licensee, or any of its officers or directors (or any of its Affiliates, Sublicensees or Third Party contractors or any of their respective officers and directors) has been in Violation. After the Effective Date, Licensee shall notify Licensor in writing immediately if any such Violation occurs or comes to its attention.

 

(g) Obligation to Notify.

Licensee shall promptly notify Licensor upon becoming aware of any violation of any anti-corruption laws by Licensee or its Affiliate or those acting on Licensee’s behalf in connection with the matters that are the subject of this Agreement and the performance by Licensee of its obligations hereunder.

 

(h) Compliance Audits.

Licensee shall maintain books and records that are complete and accurate in all material respects relating to its compliance by Licensee and its Affiliates that is engaged in carrying out activities in connection with this Agreement with anti-corruption laws and with respect to its obligations under this Agreement (collectively, the “Compliance Records”) for a period of two (2) years after the period to which such records relate or such longer period as required by Applicable Laws, which Compliance Records shall include: (a) its policies and procedures including those of Licensee and its Affiliates concerning compliance with anti-corruption laws with respect to its obligations under this Agreement, (b) records of any investigations and remedial and disciplinary actions undertaken to address material violations of anti-corruption laws with respect to its obligations under this Agreement and (c) records of any payments made by it or Licensee and its Affiliates in connection with this Agreement. Upon reasonable advance written notice to Licensee, Licensor shall be entitled, at its cost and expense, to have access to and audit the Compliance Records of Licensee and any of its Affiliates (to the extent such Compliance Records are not subject to attorney-client privilege) for a period of two (2) years after the period to which such records relate or such longer period as required by applicable anti-corruption laws. Licensor may not exercise this audit right more frequently than once during any twelve (12)-month period; provided, however, that if any audit by Licensor under this Section 4.2(h) reveals that Licensee or any of its Affiliates is or was not in material compliance with applicable anti-corruption laws in relation to the performance of its obligations under this Agreement, Licensor shall have the right to conduct such additional audits (for clarity, such additional audits shall apply only to the applicable Licensee and its Affiliates which was so determined during the initial audit in such twelve (12)-month period to not be in material compliance) during such twelve (12)-month period as may be reasonably required to determine whether Sub-Licensee and its Affiliates have appropriately remedied such non-compliance.

 

4.3. Termination for Non-Compliance.

Any uncured violation by Licensee or any of its Affiliates of any applicable anti-corruption laws in connection with its obligations under this Agreement shall be a material breach of this Agreement entitling Sub-Licensor to terminate this Agreement pursuant to Section 11.2(c).

 

4.4. Responsibility for Compliance.

Licensee acknowledges and agrees that neither Licensor, nor or any of its Affiliates or Licensor’s or its Affiliates’ officers, directors, employees, agents and representatives is authorized to waive compliance with the provisions of Section 4.3 and/or to give any direction, either written or oral, relating to the making of any commitment by Licensee or its agents to any Third Party in violation of the terms of this ARTICLE 4, and that Sub-Licensee shall be solely responsible for its compliance with all applicable anti-corruption laws irrespective of any act or omission of Merck or any of Merck’s Affiliates or Merck’s or its Affiliates’ officers, directors, employees, agents and representatives.

 

KASAN_기술이전, 라이선스, 특허실시, 공동연구개발 등 국제계약서, 영문계약서에서 미국법 FCPA, Anti-C

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 6. 5. 12:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

1 (공정의무)

 1) 양 당사자(그 임직원을 포함)는 본 계약의 체결, 이행 및 유지에 있어 거래의 공정성에 대한 확보가 중요한 전제 조건임을 인식하고, 타방 당사자(그와 동일시 할 수 있는 친인척 등 관계자 포함) 또는 본 계약과 관련한 제3(이하 거래 상대방이라 한다)에 대하여 거래의 공정성을 해할 수 있는 행위(이하 "비위행위라 한다)를 하여서는 아니 된다. "비위행위"의 예는 다음 각 호에 열거되어 있는 바와 같으며, 이에 한하지 아니한다.

금전을 제공하는 행위

사회통념수준을 초과하는 선물 또는 식사를 제공하는 행위

불건전 업소, 오락, 골프, 스키 등의 향응 및 접대를 하는 행위

출장지원, 개인 휴가 지원, 사무실 비품 제공, 협찬/찬조 등의 편의를 제공하는 행위

차용/매입/매도, 부채상환, 보증, 금전대차 등 금전 또는 부동산 관련 모든 거래행위

공동투자 및 공동재산의 취득 기회를 제공하거나, 합작투자 또는 거래 상대방의 회사에 겸직하도록 하는 행위

거래 상대방의 주식이나 기타 관련업체의 주식을 제공 또는 투자하도록 하거나 기타 재산을 공동 투자 또는 취득하도록 하는 행위

고용보장, 취업알선의 약속 등 미래에 대한 보장을 하는 행위

기타 타방 당사자의 정도경영 준수사항을 위반하거나, “거래 상대방이 공정하게 업무를 수행하는 데 지장을 초래하는 행위

 

2) 양 당사자는 거래 공정성 확보를 위해 다음 각 호의 사항을 협조하도록 한다.

타방 당사자의 임직원을 상대로 일방 당사자의 임직원 등에 의해 이루어진 비위행위가 발견되거나 비위행위에 대한 의혹이 있는 경우, 양 당사자는 그와 관련된 자료의 제출 또는 열람을 상대방 당사자에게 요구할 수 있으며, 이 경우 양 당사자는 해당 요구에 적극 협조하여야 한다.

일방 당사자는 타방 당사자의 임직원으로부터 본 조 제1항 각 호의 행위를 제의받거나, 이러한 사실을 인지한 때에는 타방 당사자의 관련 부서에 즉각 신고토록 한다.

양 당사자는 본 계약 외에 상대 당사자의 정도경영 실천에 적극 협조한다.

 

3) 본 조는 본 계약의 종료(만료, 해지 또는 해제 포함) 후에도 유효하다.

 

4) 본 계약의 일방 당사자가 본 조항의 공정의무를 위반한 경우 그 상대방은 본 계약을 즉시 해지할 수 있다.

 

KASAN_기술이전, 라이선스, 특허실시, 공동연구개발 등 국문계약서에서 공정의무, 반부패의무, 비위행위금지, An

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 6. 5. 11:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

KASAN_국제계약, 영문계약에서 Anti-Corruption, Compliance 쟁점, 미국법 FCPA 관련 주

 

[질문 또는 상담신청 입력하기]

 

 

 

작성일시 : 2019. 6. 5. 09:16
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

17. TERM AND TERMINATION. 

17.1 Termination Prior to the Closing Date.

This Agreement may be terminated at any time prior to the Closing Date (with respect to Sections 17.1(b) and 17.1(c) below, by written notice by the terminating Party to the other Party): (a) by mutual written agreement of the Parties;

 

(b) by Licensor or Licensee, if a court of competent jurisdiction or other Governmental Authority shall have issued a non-appealable final order, decree or ruling or taken any other non-appealable final action, in each case, having the effect of permanently restraining, enjoining or otherwise prohibiting the transactions contemplated by this Agreement; provided, however, that the right to terminate this Agreement under this Section 17.1(b) shall not be available to any Party whose failure to fulfill any obligation under this Agreement has been the primary cause of, or materially contributed to, such action; or

 

(c) by Licensee, if Licensor has breached any representation, warranty, covenant or agreement of Licensor set forth in this Agreement which (i) would result in a failure of a condition set forth in Section 13.2 and (ii) is not cured within thirty (30) calendar days after written notice thereof.   

 

17.2 Term.

Except as provided in Section 17.1, this Agreement shall continue until the date of expiration of the Royalty Term, unless earlier terminated in accordance with this Article 17 (the “Term”).  

 

17.3 Termination of the Agreement After the Closing Date.  

 

(a) Termination by Licensee. 

Licensee may terminate this Agreement in its entirety or in part (including, for example, on a country-by-country basis) for any reason (a) upon at least ninety (90) days prior written notice to Licensor if such notice is delivered prior to the First Commercial Sale of a Licensed Product anywhere in the Territory or (b) upon at least one hundred eighty (180) days prior written notice to Licensor if such notice is delivered after the First Commercial Sale of a Licensed Product anywhere in the Territory.  In the event of any significant adverse clinical events or the termination of a Clinical Trial for safety reasons and Licensee terminates this Agreement under this Section 17.3(a), the foregoing notice periods in clauses (a) and (b) shall be reduced to forty-five (45) days and ninety (90) days, respectively.

 

(b) Termination for Material Breach. 

If either Party believes the other is in material breach of its obligations under this Agreement, it may give notice of such breach to the other Party, which Party shall have sixty (60) days in which to remedy such breach, or thirty (30) days in the case of material breach of any payment obligation hereunder.

 

Such sixty (60) day period shall be extended in the case of a breach not capable of being remedied in such sixty (60) day period so long as the breaching Party uses diligent efforts to remedy such breach and is pursuing a course of action that, if successful, will effect such a remedy; provided, however, that such cure period shall not be extended more than sixty (60) additional days. 

 

If such alleged breach is not remedied or is not capable of being remedied within the period set forth above, the non-breaching Party shall be entitled, without prejudice to any of its other rights conferred on it by this Agreement, and in addition to any other remedies available to it by law or in equity, to terminate this Agreement upon written notice to the other Party.  In the event of a dispute regarding any payments due and owing hereunder, all undisputed amounts shall be paid when due and the balance, if any, shall be paid promptly after settlement of the dispute including any accrued interest thereon.  

 

(c) Consequences of Termination. 

In the event that either Party terminates this Agreement, then as of the effective date of such termination, the following terms and conditions shall apply:

 

(i) Termination by Licensor for Licensee’s Material Breach. 

In the event of termination of this Agreement by Licensor pursuant to Section 17.3(b) for Licensee’s uncured material breach, and except for each Party’s rights and obligations that survive termination as set forth in Section 17.5:

 

(A) all licenses and rights granted by either Party under this Agreement shall terminate with the exception, subject to Section 19.1, of the license granted to Licensor by Licensee under the Licensee Inventions relating to formulations or methods of manufacturing formulations derived from the Licensed Intellectual Property pursuant to Section 9.2(c) which shall become perpetual, worldwide and fully paid; 

 

(B) Licensee shall pay Licensor any and all payments that have accrued prior to the effective date of such termination; 

 

(C) Licensee shall transfer to Licensor all materials, results, analyses, reports, websites, marketing materials, technology, know-how and other Information in whatever form received by Licensee from Licensor as of the effective date of such termination; 

 

(D) Licensee shall transfer to Licensor (A) all Regulatory Approvals in the Territory in effect as of the date of such termination and/or (B) any and all Information pertaining to the Development and Commercialization of the Licensed Products in the Territory, including but not limited to any and all Clinical Trial data pertaining to the Territory. 

 

(ii) Termination by Licensee. 

Subject to Section 17.3(c)(ii)(E), in the event of termination of this Agreement by Licensee pursuant to Section 17.3(a), and except for each Party’s rights and obligations that survive termination as set forth in Section 17.5:  

 

(A) all licenses and rights granted by either Party under this Agreement shall terminate, with the exception, subject to Section 19.1, of the license granted to Licensor by Licensee under the Licensee Inventions relating to formulations or methods of manufacturing formulations derived from the Licensed Intellectual Property pursuant to Section 9.2(c), which shall become worldwide, subject to Licensor’s obligations under subsection (E) below;  

 

(B) Licensee shall pay Licensor any and all payments that have accrued prior to the effective date of such termination; 

 

(C) Licensee shall transfer to Licensor all materials, results, analyses, reports, websites, marketing materials, technology, know-how and other Information in whatever form received by Licensee from Licensor as of the effective date of such termination;  

 

(D) Licensee shall, upon receipt of reasonable consideration from Licensor based on an actual cost basis, transfer to Licensor (A) all Regulatory Approvals in the Territory in effect as of the date of such termination and/or (B) any and all Information pertaining to the Development and Commercialization of the Licensed Products in the Territory, including but not limited to any and all Clinical Trial data pertaining to the Territory; and 

 

(E) in partial consideration for (A) Licensee’s costs of obtaining and maintaining such Regulatory Approvals and Commercializing Licensed Products in the Territory prior to the date of such termination, and/or (B) subject to Section 19.1, the license granted under the Licensee Inventions, Licensor shall pay to Licensee following the effective date of such termination, on a product-by-product and country-by-country basis, a commercially reasonable royalty to be negotiated in good faith by the Parties, on all sales by Licensor, its Affiliates and Sublicensees, of products that would have been Licensed Products, had they been sold by Licensee prior to the effective date of such termination. 

 

(iii) Termination by Licensee for Licensor’s Material Breach.  

In the event that Licensee has the right to terminate this Agreement for Licensor’s uncured material breach pursuant to Section 17.3(b), Licensee may terminate this Agreement or, in lieu of such termination, by written notice to Licensor after a determination that such breach was a material breach and was not cured before the expiration of the cure period set forth in Section 17.3(b), elect to retain all of the rights and licenses granted to Licensee hereunder for the remainder of the Term. Following such an election by Licensee:

 

(A) Licensee may request that damages be awarded to Licensee for Licensor’s uncured material breach by final and binding arbitration conducted in accordance with Section 19.12. In determining whether damages should be awarded to Licensee, the arbitrators shall consider the nature of Licensor’s uncured material breach and the impact of such uncured material breach on Licensee and the transactions contemplated by this Agreement. 

 

In the event that such final and binding arbitration determines that Licensee should be awarded damages, Licensee shall be entitled to deduct the amount of such damages from milestone and royalty payments to be paid to Licensor under Sections 8.2 and 8.3;

 

(B) the limitations applicable to Licensor’s activities as set forth in Sections 2.3(a) and 2.4 shall continue to apply; and

 

(C) the license granted by Licensee to Licensor under Section 9.2(c) shall terminate.    

 

17.4 Surviving Obligations. 

Upon termination of this Agreement, the Parties shall remain obligated to make all payments which have accrued under this Agreement prior to the date of termination, when and as they become due and payable.  In addition, the provisions in Articles 1, 9, 10, 14, 15, 16, 18 and 19, and Sections 2.6, 5.2, 5.7, 7.6, 8.3(h), 8.7 (with respect to payment accruing prior to the effective date of termination), 8.8, 8.9, 17.3(c), 17.4 and 17.5 of this Agreement shall survive termination of this Agreement for any reason.  

 

17.5 Accrued Rights. 

Termination or expiration of this Agreement shall not relieve either Party from obligations that are expressly indicated to survive termination or expiration of the Agreement.  Termination by a Party shall not be an exclusive remedy and all other remedies will be available to the terminating Party, in equity and at law.

 

KASAN_국제계약, 영문계약, 특허실시, 영업비밀, 기술이전 라이선스 계약서에서 계약종료, 계약해지, TERMIN

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 6. 4. 13:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

ARTICLE 2 - TECHNICAL ASSISTANCE

2.1   TECHNICAL DOCUMENTATION

           (a) Licensor shall furnish to Licensee, in accordance with the time schedule to be agreed upon between the Parties, one (1) set of hard copies of the Technical Documentation. If Licensee discovers that any of the documents are missing or illegible or damaged, Licensee shall inform Licensor in writing and Licensor shall make such documents available for Licensee within twenty (20) days of receiving such notice.

                                                             

           (b) The foregoing Technical Documentation to be furnished under paragraph 2.1 (a) above shall be delivered to Licensee and shall be the latest version as of the time it is delivered or sent.

 

           (c) Licensee shall pay Licensor for any additional copies of the Technical Documentation requested by Licensee at the rates agreed upon in writing by both Parties prior to sending.

 

           (d) Nothing in this Agreement shall be construed to require that Licensor furnish Licensee with any technical information on any products other than Licensed Product or any technical information which may not be furnished because of a government contract, act, regulation or restriction or the proprietary interest of a third party.

 

           (e) Errors in Technical Documentation. Each Party shall promptly advise the other of any significant error it may discover in the Technical Documentation. In that event, Licensor shall correct any error in the Technical Documentation and shall furnish such corrected Technical Documentation to Licensee without charge.

 

(f) Strict Compliance with Technical Documentation. In order to maintain the quality of the Licensed Products manufactured and assembled by Licensee pursuant to this Agreement, Licensee shall manufacture and/or assemble the Licensed Products in strict accordance with the standards and specifications stated in the Technical Documentation provided by Licensor and as otherwise specified by Licensor. Licensee shall exercise the utmost care in the selection of the materials and parts to be used and incorporated into the Licensed Products.

 

2.2      ASSISTANCE BY LICENSOR

Licensor shall provide reasonable assistance in the use of the Technical Documentation to the extent such assistance is reasonably necessary for Licensee to make use of the Technical Documentation to manufacture the Licensed Product. Such assistance may include, but will not be limited to, technical assistance, training, testing and limited application engineering services.

 

- 라이센서의 조력의무를 선언적으로 규정한 조항임. 제조에 필요한 기술정보 활용을 가능케 하도록 조력의무를 규정하고 있어 상당히 포괄적임.

- 이하에서 구제적인 비용을 규정할 경우 라이센서의 수입원이 되지만, 그렇지 않을 경우 부담조항이 될 수 있음.

                                                                           

2.3   TECHNICAL ASSISTANCE

      (a) At the request of Licensee, Licensor shall, at times agreed upon by the Parties, dispatch its engineers to Licensee to provide technical assistance on matters concerning the use of the Technical Documentation during the Technical Cooperation Period. All costs and expenses of such Licensor's personnel dispatched to Licensee shall be borne, or reimbursed to Licensor, by Licensee and shall include:

            (i)   round trip economic air fare between Korea and China;

            (ii)  suitable accommodations, meals, traveling and transportation expenses in China and other reasonable charges in connection with the performance of their duties hereunder;

            (iii) wage and daily allowance, payable to Licensor, on its demand, amounting to U$500 per Man Day for Licensor's personnel;

 

      (b) Licensee shall take appropriate steps necessary to protect and ensure the safety of Licensor's personnel and their property, including without limitation, against war, war-like operation, terror, revolution, civil commotion, catastrophe and acts of public enemies. Licensor reserves the right to  instruct any or all of its dispatched personnel to return to Korea, or such other place as it may designate, at Licensee's expense  when, in Licensor's sole judgment , one of the above-mentioned situations arises which may endanger the safety and well-being of such personnel.

- 기술자 파견에 따른 안전보장은 실시자 부담임

 

      (c) Licensee is responsible for obtaining any permits or authorizations required for Licensor's personnel to enter China to provide services hereunder, and to bring any related materials required by Licensor.

- 기술자 파견에 따른 출입국 보장은 실시자 부담

 

    (d) The number of such personnel, the period of their stay at Licensee's plant and other terms and conditions not set forth herein shall be agreed upon between the Parties on a case by case basis.

 

2.4   TRAINING

At the request of Licensee, Licensor will, during the Technical Cooperation Period, provide training on the use of the Technical Documentation for Licensee's employees (the "Trainees") at Licensor's place or other places designated by Licensor, subject to the following terms and conditions:

      (i) Licensor and Licensee shall agree on the most efficient training program for the Trainees;

      (ii) Licensee shall bear all the cost and expenses relating to the Trainees, including but not limited to their salaries, round trip airfare between China and Korea, lodgings and meals of Trainees in Korea, transportation and insurance;

      (iii) Licensor shall provide working lunches for the trainees during working days and transportation for the trainees between dormitory and training site.

      (iv) Licensee shall pay to Licensor as training fee, payable upon demand, US$300 per Trainee per day, as the compensation of training services provided by Licensor;

      (v) Licensee shall instruct the Trainees to observe and abide by all rules and regulations of Licensor and the laws of Korea during their training period;

      (vi) All Trainees shall be insured at the expense of Licensee by an internationally recognized accident compensation insurance during the entire training period between their departure from and return to China;

      (vii) Licensee shall indemnify and hold harmless Licensor against any loss, damage, claim, liabilities, cost or expense arising out of any act of a Trainee or any injury or death of the Trainee or any damage to his/her property.

 

2.5   SUPPORT OF TESTS

Pursuant to the terms of a purchase order, sale agreement or other document to be separately agreed by the Parties or Licensee and Delphi, Licensor will support the necessary manufacturing Part Production Approval Process validation tests for the Licensed Products.

 

2.6   SAMPLE TEST AND VERIFICATION

Before distribution and sale of any of the Licensed Product manufactured or assembled hereunder, Licensee shall submit, at its expense, samples of the Licensed Product for approval by Licensor. Licensor shall promptly conduct appropriate tests on such samples and advise Licensee of the results thereof. The costs of any tests on the samples shall be responsibility of Licensee, and Licensor shall advise Licensee of the test fees in advance.

 

KASAN_국제계약, 영문계약, 특허실시, 영업비밀, 기술이전 라이선스 계약서에서 기술지원 TECHNICAL ASS

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 6. 4. 08:47
Trackback 0 : Comment 0

댓글을 달아 주세요


11. REPRESENTATIONS AND WARRANTIES.

11.1 The Parties ’Representations and Warranties.

Each Party hereby represents, warrants and covenants to the other Party, as of the Effective Date (or as of the Closing Date in the case of Section 11.1(h)), that:

(a) such Party (i) is a corporation duly organized and validly existing under the laws of its jurisdiction of organization, and (ii) has full power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as it is contemplated to be conducted by this Agreement;

 

(b) such Party has sufficient legal and/or beneficial title under its intellectual property rights necessary for the purposes contemplated under this Agreement and to grant the licenses contained in this Agreement;

 

(c) such Party is not aware of any pending or threatened litigation, nor has it received any notice of claim, alleging that it has violated or would violate, through the manufacture, import and/or sale of Licensed Products hereunder, or by conducting its obligations as currently proposed under this Agreement, any intellectual property or other rights of any Third Party;

 

(d) to such Party’s knowledge, all of its employees, officers, independent contractors, consultants and agents have executed agreements requiring assignment to such Party of all inventions made during the course of and as a result of their association with such Party and obligating the individual to maintain as confidential the Confidential Information of such Party;

 

(e) such Party has the power, authority and legal right, and is free to enter into this Agreement and, in so doing, will not violate any other agreement to which such Party is a party as of the Effective Date and such Party has maintained and will maintain and keep in full force and effect all agreements and regulatory filings necessary to perform its obligations under the Agreement and, during the Term, such Party shall not enter into any agreement with a Third Party that will conflict with the rights granted to the other Party under this Agreement;

 

(f) this Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid and binding obligation of such Party and is enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability of specific performance and general principles of equity;

 

(g) such Party has taken all corporate action necessary to authorize the execution, delivery and performance of this Agreement;

 

(h) such Party has obtained all consents, approvals and authorizations of all Regulatory Authorities and other Third Parties reasonably deemed necessary by such Party to be obtained in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder;

 

(i) the execution and delivery of this Agreement and the performance of such Party’s obligations hereunder: (i) do not conflict with or violate any provision of the certificate of incorporation, bylaws, limited partnership agreement or any similar instrument of such Party, as applicable, in any material way; (ii) to such Party’s knowledge, do not conflict with, violate or breach or constitute a default or require any consent under any indenture, mortgage, contract or instrument to which it is party or by which it is bound; and (iii) to such Party’s knowledge, do not conflict with, violate, or breach or constitute a default or require any consent under, any requirement of Applicable Laws or court or administrative order by which such Party is bound;

 

(j) except in connection with or related to the settlement between Licensee A and the United States Department of Justice, announced on September 1, 2010, neither such Party, nor any of such Party’s employees, officers, independent contractors, consultants or agents who will render services relating to Licensed Products: (i) has ever been debarred or is subject to debarment or convicted of a crime for which an entity or person could be debarred under 21 U.S.C. Section 335a; or (ii) has ever been under indictment for a crime for which a person or entity could be debarred under said Section 335a. If during the Term a Party has reason to believe that it or any of its employees, officers, independent contractors, consultants or agents rendering services relating to Licensed Products: (x) is or will be debarred or convicted of a crime under 21 U.S.C. Section 335a; or (y) is or will be under indictment under said Section 335a, then such Party shall immediately notify the other Party of same in writing; and

 

(k) such Party currently has no research or development project, or agreement with any Third Party, that, in such Party’s reasonable scientific or business judgement, (i) requires or is likely to require changes to the Development Plan attached hereto as Exhibit 4.1, or (ii) is likely to interfere with such Party’s ability to enter into and perform its obligations under this Agreement.

 

11.2 Representations and Warranties of Licensor M.

Licensor M hereby represents, and warrants and covenants to Licensee A, as of the Effective Date, that:

(a) Licensor M is the sole and exclusive owner of all right, title and interest, in, to and under the Licensed Intellectual Property in the Territory;

 

(b) M is the sole and exclusive owner of all right, title and interest, in, to under the Licensed Intellectual Property necessary or useful in the Manufacture of Licensed Products;

 

(c) M has sufficient rights to grant the rights and licenses granted herein, free and clear of any security interests, claims, encumbrances or charges of any kind that would conflict in any material respect with the rights and licenses granted hereunder;

 

(d) M has not assigned or granted to any Third Party any rights under the Licensed Intellectual Property that cover Licensed Products in the Territory except as granted to independent contractors in the ordinary course of business in connection with M's research, Development and Manufacturing of Licensed Products, and consistent with the terms and intent of this Agreement;

 

(e) (i) M has not received any written notice from any Third Party asserting or alleging that any Development, Manufacturing, or Commercialization of the Licensed Products has infringed or misappropriated any Patent or intellectual property right of such Third Party, (ii) to the knowledge of M, the manufacture, use, offer for sale, sale or importation of Licensed Products in the Territory has not infringed and, as of the Effective Date, will not infringe, any Patent of any Third Party or misappropriate any technology of any Third Party, and (iii) there are no pending, and, to the knowledge of M, no threatened, adverse actions, suits, arbitrations, litigations, or proceedings of any nature, civil, criminal, regulatory or otherwise, in law or in equity, against M or any of its Affiliates alleging that the Development, Manufacture, Commercialization or other exploitation of Licensed Products has infringed any Patent, or misappropriated any intellectual property right of any Third Party;

 

(f) to Licensor M’s knowledge, the issued Patents within the M Patent Rights in the Territory are valid and enforceable;

 

(g) all applicable maintenance and renewal fees with respect to the M Patent Rights in the Territory have been paid and all documents, and certificates required to be filed for the purpose of maintaining such M Patent Rights have been filed;

 

(h) to Licensor M’s knowledge, no Third Party has asserted that any Licensed Intellectual Property is invalid or not enforceable;

 

(i) (i) other than as disclosed by M in writing to A prior to the Effective Date, none of the M Patent Rights, were developed with federal or state funding from any Governmental Authority, (ii) no Governmental Authority has any march in rights or other rights to use the Licensed Intellectual Property in the Territory, and (iii) neither the execution and delivery of this Agreement nor the performance hereof by M will result in the breach of, or give rise to, any right of termination, rescission, renegotiation or acceleration under, or trigger any other rights under, any agreement or contract to which M is a party, or to which it may be subject, that relates to the Licensed Products;

 

(j) no written communication has been received by M from any Third Party that alleges, and there is no pending litigation that alleges, that (i) any issued M Patent is invalid or unenforceable as of the Effective Date, or (ii) any patent application included in the M Patents, if issued, would be, invalid or unenforceable;

 

(k) to the knowledge of Licensor M, no Third Party (i) is infringing any M Patent Rights or has misappropriated any M Know-How, or (ii) has challenged the ownership, scope, duration, validity, enforceability, priority or right to use any M Patent Rights (including, by way of example, through the institution of or written threat of institution of interference, re-examination, review, supplemental examination, derivation proceeding, protest, opposition, nullity or similar invalidity proceeding before the U.S. Patent and Trademark Office or any analogous foreign entity) or any M Know-How;

 

(l) the Licensed Intellectual Property licensed to Licensee A hereunder constitutes all of the intellectual property rights Controlled by M that are necessary for A to Commercialize Licensed Products in the Territory;

 

(m) to Licensor M’s knowledge, M has complied in all material respects with all Applicable Laws in the prosecution and maintenance of the M Patent Rights in the Territory;

 

(n) all of Licensor M’s and its Affiliates’ employees, officers, and consultants/contractors involved in the research, Manufacture or Development of Licensed Products are and have been obligated to assign to M or such Affiliate, as the case may be, all Inventions claimed in the M Patent Rights and to maintain as confidential the Confidential Information of M or such Affiliate, as applicable; and

 

(o) all inventors of any Inventions included within the M Patent Rights and M Know-How have assigned their entire right, title, and interest in and to such Inventions and the corresponding Patents and Information to M and have been listed in the M Patent Rights as inventors.

 

KASAN_특허기술, 영업비밀 실시허락, 기술이전, 라이선스 영문계약서에서 진술 및 보증조항 REPRESENTATI

 

[질문 또는 상담신청 입력하기]

 

 

 

작성일시 : 2019. 5. 31. 16:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

KASAN_특허실시, 기술이전, 공동연구개발, 라이선스 등 국제계약에서 분쟁해결수단 중재조항 관련된 분쟁사례 및 실

 

[질문 또는 상담신청 입력하기]

 

 

 

작성일시 : 2019. 5. 29. 16:01
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

조정 정의

조정(Mediation)은 분쟁 당사자가 조정인의 도움을 받아 당사자 사이의 대화와 상호양해를 통하여 조리(條理)를 바탕으로 분쟁을 실정에 맞게 자율적으로 해결하는 제도입니다. 중립적인 제3자인 조정인이 분쟁 당사자간의 합의를 통해 분쟁을 해결하도록 도와주는 ADR 제도 중의 하나가 조정(調停)입니다.

 

분쟁을 조정에 의하여 해결하기로 하는 합의를 조정합의(調停合意)라고 합니다. 대한상사중재원의 조정을 이용하기 위해서는 분쟁 당사자간에 체결한 계약서나 합의서 등에 '대한상사중재원의 조정규칙에 의한 조정 또는 대한상사중재원의 조정에 따라 해결하기로 합의한 경우' 즉 조정합의가 있는 경우에 해당하여야 합니다.

 

조정합의는 사전 합의(조정 조항)사후 조정합의 형식으로 할 수 있습니다.

 

당사자간에 조정합의가 없는 경우나 사후 조정합의가 곤란한 경우 일방 당사자(신청인)는 중재원에 조정참여 권유요청을 할 수 있습니다. 이 경우 중재원은 타방 당사자(피신청인)에게 조정참여 권유요청을 하고, 피신청인이 동의하면 조정절차를 진행하게 됩니다.

 

조정인의 역할

조정인은 당사자들이 분쟁을 우호적으로 해결하도록 협조하여야 합니다. 조정인은 당사자간의 거래관행 및 분쟁과 관련된 제반 상황 등을 고려하여 공정하고 객관적이며, 형평과 선의 원칙에 따라 분쟁을 조정하여야 합니다. 조정인은 언제든지 구두 또는 서면으로 당사자들에게 조정안을 제시할 수 있습니다.

 

조정인의 의무

조정인은 조정에 관하여 공정성과 독립성을 유지하여야 합니다. 조정인은 그 자신의 공정성 또는 독립성에 관하여 정당한 의문을 야기시킬 수 있는 사유가 있을 때에는 지체없이 이를 사무국에 고지하여야 합니다. 사무국은 조정인으로부터 그러한 고지를 받으면 즉시 당사자들에게 통지합니다.

 

조정절차 개요

 

KASAN_대한상사중재원의 조정 (Mediation) 개요 설명 – 중재(Arbitration)와 엄격하게 구별.p

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 5. 29. 09:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

3(정의) 이 법에서 사용하는 용어의 뜻은 다음과 같다.

1. "중재"란 당사자 간의 합의로 재산권상의 분쟁 및 당사자가 화해에 의하여 해결할 수 있는 비재산권상의 분쟁을 법원의 재판에 의하지 아니하고 중재인의 판정에 의하여 해결하는 절차를 말한다.

2. "중재합의"란 계약상의 분쟁인지 여부에 관계없이 일정한 법률관계에 관하여 당사자 간에 이미 발생하였거나 앞으로 발생할 수 있는 분쟁의 전부 또는 일부를 중재에 의하여 해결하도록 하는 당사자 간의 합의를 말한다.

 

8(중재합의의 방식) ① 중재합의는 독립된 합의 또는 계약에 중재조항을 포함하는 형식으로 할 수 있다. ② 중재합의는 서면으로 하여야 한다.

 

③ 다음 각 호의 어느 하나에 해당하는 경우는 서면에 의한 중재합의로 본다.

1. 구두나 행위, 그 밖의 어떠한 수단에 의하여 이루어진 것인지 여부와 관계없이 중재합의의 내용이 기록된 경우

2. 전보, 전신, 팩스, 전자우편 또는 그 밖의 통신수단에 의하여 교환된 전자적 의사표시에 중재합의가 포함된 경우. 다만, 그 중재합의의 내용을 확인할 수 없는 경우는 제외한다.

3. 어느 한쪽 당사자가 당사자 간에 교환된 신청서 또는 답변서의 내용에 중재합의가 있는 것을 주장하고 상대방 당사자가 이에 대하여 다투지 아니하는 경우

 

④ 계약이 중재조항을 포함한 문서를 인용하고 있는 경우에는 중재합의가 있는 것으로 본다. 다만, 중재조항을 그 계약의 일부로 하고 있는 경우로 한정한다.

 

9(중재합의와 법원에의 제소) ① 중재합의의 대상인 분쟁에 관하여 소가 제기된 경우에 피고가 중재합의가 있다는 항변을 하였을 때에는 법원은 그 소를 각하하여야 한다. 다만, 중재합의가 없거나 무효이거나 효력을 상실하였거나 그 이행이 불가능한 경우에는 그러하지 아니하다. ② 피고는 제1항의 항변을 본안에 관한 최초의 변론을 할 때까지 하여야 한다. ③ 제1항의 소가 법원에 계속 중인 경우에도 중재판정부는 중재절차를 개시 또는 진행하거나 중재판정을 내릴 수 있다.

 

35(중재판정의 효력) 중재판정은 양쪽 당사자 간에 법원의 확정판결과 동일한 효력을 가진다. 다만, 38조에 따라 승인 또는 집행이 거절되는 경우에는 그러하지 아니하다.

 

36(중재판정 취소의 소) ① 중재판정에 대한 불복은 법원에 중재판정 취소의 소를 제기하는 방법으로만 할 수 있다.

 

② 법원은 다음 각 호의 어느 하나에 해당하는 경우에만 중재판정을 취소할 수 있다.

1. 중재판정의 취소를 구하는 당사자가 다음 각 목의 어느 하나에 해당하는 사실을 증명하는 경우

. 중재합의의 당사자가 해당 준거법에 따라 중재합의 당시 무능력자였던 사실 또는 중재합의가 당사자들이 지정한 법에 따라 무효이거나 그러한 지정이 없는 경우에는 대한민국의 법에 따라 무효인 사실

. 중재판정의 취소를 구하는 당사자가 중재인의 선정 또는 중재절차에 관하여 적절한 통지를 받지 못하였거나 그 밖의 사유로 변론을 할 수 없었던 사실

. 중재판정이 중재합의의 대상이 아닌 분쟁을 다룬 사실 또는 중재판정이 중재합의의 범위를 벗어난 사항을 다룬 사실. 다만, 중재판정이 중재합의의 대상에 관한 부분과 대상이 아닌 부분으로 분리될 수 있는 경우에는 대상이 아닌 중재판정 부분만을 취소할 수 있다.

. 중재판정부의 구성 또는 중재절차가 이 법의 강행규정에 반하지 아니하는 당사자 간의 합의에 따르지 아니하였거나 그러한 합의가 없는 경우에는 이 법에 따르지 아니하였다는 사실

 

2. 법원이 직권으로 다음 각 목의 어느 하나에 해당하는 사유가 있다고 인정하는 경우

. 중재판정의 대상이 된 분쟁이 대한민국의 법에 따라 중재로 해결될 수 없는 경우

. 중재판정의 승인 또는 집행이 대한민국의 선량한 풍속이나 그 밖의 사회질서에 위배되는 경우

 

③ 중재판정 취소의 소는 중재판정의 취소를 구하는 당사자가 중재판정의 정본을 받은 날부터 또는 제34조에 따른 정정ㆍ해석 또는 추가 판정의 정본을 받은 날부터 3개월 이내에 제기하여야 한다. ④ 해당 중재판정에 관하여 대한민국의 법원에서 내려진 승인 또는 집행 결정이 확정된 후에는 중재판정 취소의 소를 제기할 수 없다.

 

37(중재판정의 승인과 집행) ① 중재판정은 제38조 또는 제39조에 따른 승인 거부사유가 없으면 승인된다. 다만, 당사자의 신청이 있는 경우에는 법원은 중재판정을 승인하는 결정을 할 수 있다. ② 중재판정에 기초한 집행은 당사자의 신청에 따라 법원에서 집행결정으로 이를 허가하여야 할 수 있다. ③ 중재판정의 승인 또는 집행을 신청하는 당사자는 중재판정의 정본이나 사본을 제출하여야 한다. 다만, 중재판정이 외국어로 작성되어 있는 경우에는 한국어 번역문을 첨부하여야 한다. ④ 제1항 단서 또는 제2항의 신청이 있는 때에는 법원은 변론기일 또는 당사자 쌍방이 참여할 수 있는 심문기일을 정하고 당사자에게 이를 통지하여야 한다. ⑤ 제1항 단서 또는 제2항에 따른 결정은 이유를 적어야 한다. 다만, 변론을 거치지 아니한 경우에는 이유의 요지만을 적을 수 있다. ⑥ 제1항 단서 또는 제2항에 따른 결정에 대해서는 즉시항고를 할 수 있다. ⑦ 제6항의 즉시항고는 집행정지의 효력을 가지지 아니한다. 다만, 항고법원(재판기록이 원심법원에 남아 있을 때에는 원심법원을 말한다)은 즉시항고에 대한 결정이 있을 때까지 담보를 제공하게 하거나 담보를 제공하게 하지 아니하고 원심재판의 집행을 정지하거나 집행절차의 전부 또는 일부를 정지하도록 명할 수 있으며, 담보를 제공하게 하고 그 집행을 계속하도록 명할 수 있다. ⑧ 제7항 단서에 따른 결정에 대해서는 불복할 수 없다.

 

KASAN_중재법 주요조항 정리.pdf

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 5. 29. 08:21
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

2. LICENSE GRANT. 

2.1 License Grant to A. 

Subject to the terms and conditions of this Agreement, Licensor M hereby grants to Licensee A an exclusive (even as to M and its Affiliates), royalty-bearing license, with the right to grant sublicenses through multiple tiers (subject to Section 2.2), under the M Know-How and M Patent Rights, to Develop, manufacture, use, sell, offer for sale, import, export and otherwise Commercialize Licensed Products in the Territory subject to and in accordance with the terms and conditions of this Agreement.  The foregoing license includes the right to have any of the foregoing performed pursuant to Section 2.2.

 

2.2 Sublicense and Subcontracting Rights. 

Licensee A shall require A’s Sublicensees to agree in writing to be bound by all of the applicable terms and conditions of this Agreement. A’s grant of any sublicense shall not relieve A from any of A’s obligations under this Agreement, and A shall remain jointly and severally liable for any uncured breach of a sublicense by a Sublicensee of A to the extent that such uncured breach would constitute a breach of this Agreement. A shall have the right to retain a Third Party contractor to perform any activity in connection with A’s exercise of any of its rights granted under Section 2.1, where such activity is to be performed at the direction and control and for the sole benefit of A or its Affiliates. A shall ensure that any and all activities performed by the Third Party contractor comply in all respects with the terms and conditions of this Agreement, and shall remain primarily liable for all such activities of the Third Party contractor. Such retention of the Third Party contractor is not a sublicense within the meaning of this Section 2.2 but is considered an activity of A under the license granted in Section 2.1. 

 

2.3 Certain Restrictions.  

(a) Except as otherwise expressly provided in Section 2.4, Licensor M agrees that it shall not, and will cause its Affiliates to not, offer to sell, license or otherwise provide any rights, including for example distribution rights, to Licensed Products, or under M Patent Rights or M Know How, to any Third Party if M or its relevant Affiliates, knows, or has a reason to believe (i) that such Licensed Product would be sold or transferred into the Territory; or (ii) that M Patent Rights or M Know How would be used, directly or indirectly, to manufacture, develop or commercialize a Licensed Product, or any product that would be reasonably expected to compete with a Licensed Product, or any product that would infringe at least one Valid Claim of a M Patent Right, which product, in each case, would be sold or transferred into the Territory. M agrees that it will include a provision in any contracts with its Sublicensees obligating such party to refrain from actions described in this Section 2.3(a). 

 

(b) Licensee A agrees that it shall not, and will cause its Affiliates to not, (i) offer to sell or otherwise provide Licensed Products to any Third Party if A or its relevant Affiliates, knows, or has reason to believe that the Licensed Product offered for sale, sold or provided to such Third Party would be, directly or indirectly, sold or transferred into North Korea or into South Korea; and (ii) use or practice under any intellectual property right licensed to it under this Agreement except as expressly permitted by this Agreement.  A agrees that it will include a provision in any contracts with its Sublicensees obligating such party to refrain from such actions described in Section 2.3(b)(i) and (ii).  

 

2.4 Reservation of Rights.  

(a) Notwithstanding Section 2.1 and Section 2.3, Licensor M shall retain the right to (i) Manufacture Licensed Products and supply such Licensed Products to A pursuant to the terms of the Supply Agreement, (ii) develop, manufacture, use, sell, offer for sale, import, export and otherwise commercialize the M Products anywhere in the world, (iii) subject to Section 2.5, develop, manufacture, use, sell, offer for sale, import, export and otherwise commercialize MT10 (but not any formulation thereof other than the lyophilized formulation of M’s proprietary 150kDa botulinum toxin type A product without human serum albumin) anywhere in the world either itself or through a Third Party, and (iv) develop, manufacture and use, sell, offer for sale, import, export and otherwise commercialize, under the M Know-How and M Patent Rights, any M Product that complies with cGMP (a “cGMP M Product”) anywhere in the world either by itself or through a Third Party; provided that, notwithstanding anything to the contrary, if M develops any cGMP M Product, M shall not, and shall not license, authorize or otherwise permit any Third Party to, at any time during the Term, (A) file for Regulatory Approval of a cGMP M Product in any country in the Territory as a “biosimilar” or a “follow-on biologic” or a “subsequent entry biologic” or other comparable term under applicable regulatory regimes in such country, or (B) market, promote, sell, offer for sale, import, export or otherwise commercialize a cGMP M Product anywhere in the United States or anywhere in Canada or in any Member country of the European Union.

 

(b) Notwithstanding Section 2.1 and Section 2.3, Licensor M shall retain the right to use, sell, offer for sale, import, export and otherwise Commercialize MT10 in Japan, but only in Japan and in no other country in the Territory; provided that (i) M and A shall be co-exclusive with respect to such activities with respect to MT10 in Japan, (ii) M may not sell, offer for sale or otherwise Commercialize either MT10 in Japan through any importer or distributor on a “named patient basis” or otherwise, and (iii) M shall have no right to grant sublicense rights to any Third Party with respect to MT10 in Japan but shall have the right to grant sublicense rights to an Affiliate of M in Japan; provided that, with respect to any such Affiliate, (A) M has a one hundred percent (100%) controlling interest over any decision regarding the sale or other distribution of products by such Affiliate and (B) no competitor of A has any control or equity interest in such Affiliate, in both (A) and (B), as of the effective date of such sublicense and remains so throughout the term of the sublicense. For purposes of clarification, in the event that M grants a sublicense to an Affiliate of M pursuant to (iii) above and, at any time after the effective date of the sublicense, either (1) M does not have a one hundred percent (100%) controlling interest over any decision regarding the sale or other distribution of products by such Affiliate or (2) a competitor of A acquires any control or equity interest in such Affiliate whether by, for example, investment, acquisition or merger, M agrees that such sublicense shall terminate. In connection with such M retained right, A agrees that it shall not sell, offer for sale or otherwise Commercialize either MT10 in Japan through any importer or distributor on a “named patient basis” or otherwise.   

 

2.5 Right of First Refusal. 

If Licensor M wishes to seek Regulatory Approval for and Commercialize MT10 with any Third Party, including without limitation by way of license, partnership, joint venture, collaboration, distribution or other similar relationship, Licensee A shall have a right of first refusal to obtain an exclusive (even as to M and its Affiliates) right and license to MT10 in the Territory.  M shall present to A, prior to any discussion with any Third Party, a complete data package summarizing all available data with respect to the MT10 program and a good faith proposal of terms and conditions for A to obtain an exclusive right and license to MT10, and the Parties shall comply with the procedure set forth in this Section 2.5. The Parties shall proceed promptly to negotiate the terms of a definitive agreement, and shall use commercially reasonable efforts to do so within one hundred and twenty (120) days after initiating such negotiations. In the event that A and M have not agreed upon the material terms and conditions pursuant to which A would receive such a right and license to MT10 within such one hundred and twenty (120) day period after the initiation of discussions (the “ROFR Period”), M shall be free to discuss terms and conditions for the grant of rights and license with respect to MT10 with any Third Party; provided that the terms and conditions offered to the Third Party are not more favourable to such Third Party than those that have been offered to A.  If M has not entered into a definitive written agreement with a Third Party with respect to MT10 within nine (9) months after the later of (i) the date of the expiration of the ROFR Period and (ii) the date of the termination of the negotiations between M and A regarding the terms and conditions of a license to MT10, then M shall not offer to any Third Party any rights to MT10 unless and until M has first offered A a further right of first refusal to obtain such a license, which further right of first refusal shall operate in accordance with the terms of this Section 2.5. 

 

2.6 No Implied Rights or Licenses. 

Licensor M grants no additional rights or licenses in or to any Patent or other intellectual property right, whether by implication, estoppel or otherwise, except to the extent expressly provided for under this Agreement.

 

KASAN_특허실시, 영업비밀, 기술이전 라이선스 및 생산공급 계약서에서 LICENSE GRANT 계약조항 샘플.p

 

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 5. 28. 13:04
Trackback 0 : Comment 0

댓글을 달아 주세요


 

실무적 포인트

·         진술 및 보증 조항 Rep. & Warranty

Ø  소유권/license허여권 보증 ()

Ø  계약대상 IP의 권리 유효성 보증 (적법 등록유지 , 절대적 유효성 ×)

Ø  3자의 지재권 비침해 보증 (고의침해 ○, 기타 )

 

·         면책 Indemnification

Ø  지재권 침해 claim시 면책규정은 license, 공동연구발 계약협상에서 쟁점이 많은 규정

Ø  특허를 제외한 copyright등 기타 권리에 대해서는 indemnification을 대부분 수용하는 편이나, 특허에 대해서는 면책보장의 수용이 어려운 경우가 많음. 

Ø  전세계 특허의 사전조사는 현실적으로 불가능하고, 고의적으로 copy한 경우가 아니더라도 유사성이 존재하는 한 침해를 구성  

Ø  반면, 저작권 등의 경우는 제3자의 저작물을 copy한 경우가 아니라면, 독자개발에 의해 발명/발견된 경우는 유사성이 존재하더라도 침해를 구성치 않음 

Ø  고의침해 경우(punitive damage대상이 됨) - 무제한 배상 보장 가능

Ø  기타 지재권 침해 claim경우 - 지불금액 총액 한도내에서 합의가 합리적  

Ø  제외: - 허여 용도 외 사용, 제공기술/제품의 임의 수정, 제공 외 기술/제품과 결합, 합성 등으로 인해 침해가 발생한 경우         

 

계약조항 영문 샘플

23. INDEMNIFICATION; INSURANCE; LIMITATION OF LIABILITY. 

23.1 General Indemnification by Licensor. Licensor CyDex shall defend, indemnify and hold Licensee Hospira and its Affiliates and Sublicensees, and each of their respective directors, officers, agents and employees, harmless from and against any and all losses, judgments, damages, liabilities, settlements, penalties, fines, costs and expenses (including the reasonable costs and expenses of attorneys and other professionals) (collectively “Losses”) incurred as a result of any claim, demand, action or other proceeding (each, a “Claim”) by a Third Party, to the extent such Losses arise out of: (a) the manufacture, use, handling, promotion, marketing, distribution, importation, sale or offering for sale of Captisol by CyDex, its Affiliates or any of their agents, or (b) CyDex’s breach of this Agreement, including without limitation any of its representations and warranties set forth in Section 8, or (c) any negligent or willful misconduct by CyDex or its Affiliates or any of their respective distributors, officers, directors employees or agents, in each case to the extent that such Losses are not due to Hospira’s or any of its Affiliates’ or Sublicensees’, or any of their respective directors’, officers’, agents’ or employees’ breach of this Agreement or negligence or willful misconduct.

 

23.2 General Indemnification by Licensee. Licensee Hospira shall defend, indemnify and hold Licensor CyDex and its Affiliates, and each of their respective directors, officers, agents and employees, harmless from and against any and all Losses incurred as a result of any Claim by a Third Party, to the extent such Losses arise out of: (a) the manufacture, use, handling, promotion, marketing, distribution, importation, sale or offering for sale of the Finished Product by Hospira, its Affiliates and Sublicensees, or (b) Hospira’s breach of this Agreement, including without limitation any of its representations and warranties set forth in Section 8, or (c) any negligent or willful misconduct by Hospira or its Affiliates or any of their respective distributors, officers, directors employees or agents, in each case to the extent that such Losses are not due to CyDex’s or any of its Affiliates’ or any of their respective directors’, officers’, agents’ or employees’ breach of this Agreement or negligence or willful misconduct.

 

23.4 Procedure.

 

(a) The person intending to claim indemnification under Section 9 (an “Indemnified Party”) shall promptly notify the other party (the “Indemnifying Party”) of any Claim in respect of which the Indemnified Party intends to claim such indemnification, and a reasonable explanation of the basis for the Claim and the amount of alleged Losses to the extent of the facts then known by the Indemnified Party. (Notwithstanding the foregoing, no delay or deficiency on the part of the Indemnified Party in so notifying the Indemnifying Party will relieve the Indemnifying Party of any liability or obligation under this Agreement except to the extent the Indemnifying Party has suffered actual prejudice directly caused by the delay or other deficiency.) The Indemnifying Party shall assume the defense thereof; provided, however, that if the Indemnifying Party assumes the defense, the Indemnified Party shall have the right to employ counsel separate from counsel employed by the Indemnifying Party in any such action and to participate in the defense thereof, but the fees and expenses of such counsel employed by the Indemnified Party shall be at the sole cost and expense of the Indemnified Party unless the Indemnifying Party consents to the retention of such counsel or unless the named parties to any action or proceeding include both the Indemnifying Party and the Indemnified Party and a representation of both the Indemnifying Party and the Indemnified Party by the same counsel would be inappropriate due to the actual or potential differing interests between them. And provided further that, if the Indemnifying Party shall fail to assume the defense of and reasonably defend such Claim, the Indemnified Party shall have the right to retain or assume control of such defense and the Indemnifying Party shall pay (as incurred and on demand) the fees and expenses of counsel retained by the Indemnified Party.

 

(b) The Indemnifying Party shall not be liable for the indemnification of any Claim settled (or resolved by consent to the entry of judgment) without the written consent of the Indemnifying Party (which shall not be unreasonably withheld or delayed). Also, if the Indemnifying Party shall control the defense of any such Claim, the Indemnifying Party shall have the right to settle such Claim; provided, that the Indemnifying Party shall obtain the prior written consent (which shall not be unreasonably withheld or delayed) of the Indemnified Party before entering into any settlement of (or resolving by consent to the entry of judgment upon) such Claim unless (A) there is no finding or admission of any violation of law or any violation of the rights of any Third Party by an Indemnified Party, no requirement that the Indemnified Party admit fault or culpability, and no adverse effect on any other claims that may be made by or against the Indemnified Party and (B) the sole relief provided is monetary damages that are paid in full by the Indemnifying Party and such settlement does not require the Indemnified Party to take (or refrain from taking) any action.

 

(c) Regardless of who controls the defense, the other party hereto shall reasonably cooperate in the defense as may be requested. Without limitation, the Indemnified Party, and its directors, officers, advisers, agents and employees, shall reasonably cooperate with the Indemnifying Party and its legal representatives in the investigations of any Claim.

 

23.5 Insurance. CyDex will procure and maintain, at its own expense, for the duration of the Agreement, and for [*] thereafter if written on a claims made or occurrence reported form, the types of insurance specified below with carriers rated [*]. Best or like rating agencies:

  a. Workers’ Compensation accordance with applicable statutory requirements and shall provide a waiver of subrogation in favor of Hospira; 

  b. Employer’s Liability with a limit of liability in an amount of not less than $[***]; 

  c. Commercial General Liability including premises operations, products & completed operations, blanket contractual liability, personal injury including fire legal liability for bodily injury and property damage in an amount not less than $[***]; 

  d. Commercial Automobile Liability for owned, hired and non-owned motor vehicles with a combined single limit in an amount not less than $[*];  

  e. Excess Liability including product liability with a combined single limit in an amount of not less than $[*]; 

  f. Commercial Crime or Fidelity Bond in an amount of not less than $[*] including an endorsement for Third Party liability without the requirement of a conviction. 

  g. Cargo Legal Liability insurance covering all risks of physical loss or damage to cargo handled by CyDex. The limit of liability shall not be less than $[*]. 

 

23.6 Limitation of Liability. EXCEPT FOR (1) PERSONAL INJURY, INCLUDING DEATH, (2) TANGIBLE PROPERTY DAMAGE, (3) EACH PARTY’S INDEMNIFICATION OBLIGATIONS, (4) DAMAGES ARISING OUT OF AN INTENTIONAL BREACH OF THE CONFIDENTIALITY OBLIGATIONS HEREIN, (5) DAMAGES ARISING OUT OF CYDEX’S BREACH OF SECTION 2.4, AND (6) DAMAGES FOR WHICH CYDEX IS RESPONSIBLE PURSUANT SECTION 3.6, 3.7 OR 6.4.

 

KASAN_특허실시, 기술이전, 라이선스 영문계약서에서 진술보증, 면책조항 관련 실무적 포인트 몇 가지 면책조항

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 5. 23. 10:02
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

KASAN_특허실시, 기술이전 라이선스, 공동연구개발계약에서 추가 연구개발 결과물, 개량발명 관련 계약조항 샘플,

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 5. 23. 09:43
Trackback 0 : Comment 0

댓글을 달아 주세요